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Abstract 
Several recent studies have assessed the use of biomarkers of Acute Kidney Injury (AKI), 
but the information among patients with stone disease and those with obstructive 
uropathy is limited. For this reason, we conducted a prospective cohort study to 
determine the urinary levels of KIM-1, Total and Monomeric NGAL in patients with 
hydronephrosis secondary to renal stone disease, congenital ureteropelvic junction 
obstruction or ureteral stricture, and in a group of healthy controls in our health care 
center. Urinary biomarker concentrations were evaluated before and after surgical 
treatment. Patients with hydronephrosis showed significantly higher baseline levels of 
KIM-1 compared to those patients without hydronephrosis. KIM-1 was the only urinary 
biomarker significantly affected by the presence of hydronephrosis. Total and Monomeric 
NGAL correlated with the presence of leukocyturia. Our results show that KIM-1 is a 
promising biomarker of subclinical AKI associated with hydronephrosis in urological 
patients.  
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1 Background 
Partial or complete obstruction of the urinary tract is a common and challenging 
urological condition that may occur in patients of any age. Urinary tract obstruction can 
be classified as congenital or acquired, depending on the cause; acute or chronic, 
according to the time of evolution, and benign or malignant. Alternatively, it can be 
catalogued as upper or lower urinary tract obstruction, depending on the location as well 
as unilateral or bilateral. Obstruction of the urinary tract may be silent, can cause mild 
and longstanding symptoms or it may be the reason for an emergency treatment, such as 
patients with renal colic or acute urinary retention. The main concerns of urinary 
obstruction are pain, renal function loss, and the increased possibility of an infectious 
process. Several factors play an important role in the pathophysiology of urinary tract 
obstruction and these will be reviewed in more detail in the next sections. 
Until recently, serum creatinine was considered an accurate marker to assess global renal 
function. Many diagnostic and therapeutic decisions have been based on the levels of this 
compound in blood that does not always precisely reflect the current status of kidney 
function. Lately, several studies have been dedicated to the scrutiny of newly discovered 
kidney proteins released through blood and urine that may be used as acute kidney injury 
(AKI) markers (Nickolas, 2008; Zappitelli, 2007). Numerous markers have been 
described in different patient populations and some have been proposed as potential 
substitutes for creatinine as an objective measure of AKI.  
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The most commonly investigated biomarkers are Kidney Injury Molecule-1 (KIM-1), 
Neutrophil Gelatinase-associated Lipocalin (NGAL), cystatin C, B2-microglobulin, 
interleukin-18, osteopontin and liver-type fatty acid-binding protein (L-FABP) (Koyner, 
2010; Wasilewska, 2011). Unfortunately, few studies have addressed the diagnostic value 
of these new markers in patients with urological comorbidities, or they lack of a 
longitudinal follow-up to evaluate their real significance over time. For this reason, and in 
order to provide a thoughtful understanding of the impact of these urinary AKI markers, 
we designed and conducted this prospective cohort study in urological patients. 
Throughout this chapter, we will explore the pathophysiology of unilateral and bilateral 
urinary tract obstruction and how it affects the markers used to assess the function of the 
kidney. Special attention will be paid to AKI, with emphasis on postrenal causes, 
particularly to ureteric obstruction due to stricture or stone disease. Information about the 
most commonly used urinary markers will be presented.  A detailed description of 
hydronephrosis and the grading scales are also included. Finally, the hypotheses of our 
research project will be discussed and the possible clinical implications will be 
underlined.  
1.1 Defining urinary tract obstruction 
Urinary tract obstruction (UTO) is the term used to define the blockage to the flow of 
urine that causes elevated pressures within the collecting system of the urinary tract and 
affects the normal function of the renal unit. It is usually a mechanical problem that can 
cause renal dysfunction and occur at any level of the urinary tract, from the renal calyces 
(i.e. infundibular stenosis) to the urethral meatus (i.e. urethral stenosis). The impact of the 
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obstruction in patients´ health status is related to the location of the obstruction, the time 
of onset, the baseline renal function and the presence of risk factors for electrolyte 
imbalances or septic processes.  It is useful to classify UTO according to the etiology, 
location, bilateralism and time of onset, because this information will help to determine 
the diagnosis and proper management.  Figure 1 shows different ways of classifying 
UTO, and Table 1 lists common examples associated with each type. 
 
Figure 1: Classification of urinary tract obstruction according to the location and 
level, etiology and time of onset (Campbell-Walsh, 2012; Loo, 1988).  
 4 
 
Table 1. Most common causes of urinary tract obstruction categorized by type. 
(Adapted from Campbell-Walsh, 2012). 
 
UTO is characterized by the presence of hydronephrosis on imaging studies and most 
commonly detected by either renal ultrasound or abdominal Computerized Tomography 
imaging (CT scan). According to these studies, the presence of unilateral or bilateral 
obstruction may also give important clues about the cause. Hydronephrosis is not always 
associated with mechanical obstruction, instead, it can be related to a functional disorder 
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which leads to an impairment in urine flow, such as a hypocontractile bladder, 
vesicoureteral reflux or a non-peristaltic ureter during a pyelonephritis episode.  These 
unique conditions where hydronephrosis is not related to obstruction were not included in 
our study.  
1.2 Functional changes associated with urinary tract 
obstruction 
Renal obstruction is associated with a myriad of hemodynamic and humoral responses 
that lastly lead to a reduction in the Glomerular Filtration rate (GFR) of the renal unit.  
GFR is a dynamic process determined by 3 different intimately related elements: 
1. Glomerular ultrafiltration coefficient, which is the surface area of the glomerular 
membrane 
2. Glomerular capillary pressure influenced by afferent and efferent resistances in 
glomerular vasculature.  
3. Tubular regulation 
UTO directly affects tubular regulation and the pathophysiology is different between 
unilateral and bilateral obstruction; the ultrafiltration coefficient and the capillary 
pressures may be affected in late phases of obstruction. Our knowledge comes from 
animal experiments where an increased hydrostatic pressure in the tubular system 
activates the cascade of events leading to renal fibrosis, although the complete kidney 
response to these dynamic changes is not fully understood (Vaughan, 2004). Specific and 
detailed description of the molecular biology of the kidney physiology is beyond the 
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scope of this research, and we will focus on the hemodynamic and humoral changes 
associated with urinary obstruction. 
1.2.1 Pathophysiology of unilateral ureteral obstruction  
The first study to evaluate kidney injury after complete unilateral ureteral occlusion was 
carried out in the late 1960s, with a canine model measuring vascular and ureteral 
pressures (Gillenwater, 1970). In fact, this was the foundation for further research in 
renin-angiotensine-aldosterone system (RAAS), thromboxane A2 (TA2), and other 
prostaglandins. Renal blood flow and ureteral pressures associated with unilateral 
obstruction have a relationship that is described as a “triphasic response”, that proceeds 
as follows: Phase 1) an increase in both the renal blood flow (RBF) and ureteral pressure 
(UP) is followed by phase 2) with a drop in blood flow and elevated UP, and finally 
phase 3) a decrease in both flow and pressure.  
This response was depicted after an 18-hour evaluation of unilateral ureteral obstruction 
(UUO) in a canine model and it is currently valid to understand the pathophysiology of 
complete UUO. Figure 2 shows the 3 phases initially described by Moody et al in 1975 
and several new findings have augmented our knowledge about this topic, where 
biochemical and hormonal interactions modulate renal responses.  
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Figure 2: Triphasic relationship between the renal blood flow and ureteral 
pressure after unilateral obstruction (From Loo, 1988; with permission from 
Springer). 
 
During the first two hours, the increased UP causes an immediate response regulated by 
Prostaglandin E2 (PGE2) and Nitrous Oxide to increase the RBF and maintain the normal 
GFR (Salvamini, 1994; Vaughan, 2004). This increment in UP depends on the GFR 
which affects the urine production, the tubular fluid reabsorption and the compliance of 
collecting system, especially of the renal pelvis. The second phase is characterized by a 
 8 
decrease in the RBF due to contraction of the afferent arteriole at the glomerulus by the 
activation of the RAAS and TA2. The tubular and UP remain elevated in this phase as 
consequence of the initial increase in RBF, but as time passes, the pressure in tubular and 
collecting systems decreases because the GF ceases as the RBF diminishes. 
All the aforementioned changes occur in the acute setting, and patients with a 
contralateral healthy kidney usually do not exhibit clinical or classic biochemical signs of 
AKI. Unfortunately, animal studies have documented pathological changes including 
fibrosis in renal tissue during the first days and weeks of obstruction, despite a normal 
contralateral kidney (Guerin, 2008; Nagle, 1978).  Hou et al, after analyzing the efficacy 
of micro-CT scans to detect structural changes during complete UUO in a murine model, 
found histological fibrotic changes in renal tissue after 7 days of obstruction. Evidence of 
tubular atrophy and interstitial presence of inflammatory cells were evident after two 
weeks of obstruction (Hou, 2015).  No human studies have evaluated the mechanisms of 
renal atrophy after acute urinary obstruction, but it is accepted that these changes also 
occur in humans.  
In clinical practice, chronic hydronephrosis results from a more dynamic process, where 
the obstruction is gradual and usually incomplete, a key factor that may decrease the 
ureteral pressure and the subsequent hemodynamic response. Although, the evidence 
suggests that obstruction of the upper urinary tract leads the cascade of inflammatory and 
fibrotic mechanisms in renal parenchyma. Some models have been studied and will be 
discussed later in this chapter.  
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1.2.2 Pathophysiology of bilateral ureteral obstruction or 
obstruction in a solitary kidney model 
The model of bilateral obstruction or complete obstruction in solitary kidneys differs 
from the unilateral model by the absence of a contralateral unit that filtrates and 
eliminates the vasoactive substances that may affect the “triphasic response”. The 
accumulation of biochemical mediators causes a transient increment in renal blood flow 
with prolonged elevation in UP decreasing the eGFR. The absence of a normal 
contralateral kidney precludes the elimination of inflammatory mediators, increasing the 
inflammatory response, the cellular damage and the accumulation of waste products such 
as urea and creatinine. These changes are acute and their clinical implications can be 
catastrophic, requiring urgent management to relieve obstruction and avoid metabolic 
complications related to renal failure. This topic is beyond the scope of this research 
project, as we focused in those cases with subclinical AKI not requiring urgent 
management. 
The following figure is intended to integrate the functional, hemodynamic and 
biochemical changes in unilateral and bilateral ureteral obstruction, which finally lead to 
a cellular fibrotic response. We also show the specific time when the most common 
markers of AKI are detected to demonstrate their relationship with the pathophysiologic 
process of renal injury. The new AKI markers are released in the early phase of 
obstruction, making them potential indicators of early renal injury.  
 10 
 
Figure 3: Functional changes following unilateral and bilateral obstruction and 
markers of kidney injury (Adapted with information from Bellomo, 2012; 
Campbell-Walsh, 2012; Loo 1988). 
 
1.2.3 Partial ureteral obstruction 
Some researchers investigating the deleterious effects of partial ureteral occlusion have 
used neonatal animal models to evaluate the changes in cellular differentiation and 
development (Sugandhi, 2014; Wen, 1998). Glomerular and tubular structures are 
compromised and the overall renal function is affected. This process is likely similar to 
what happens in newborn patients with prenatal hydronephrosis and posterior urethral 
valves who have chronic kidney disease related to renal dysplasia.  
Unilateral 
Obstruction
Bilateral 
Obstruction
Abbreviations: Cys C, Cystatine C; GFR, glomerular filtration rate; IL-18, Interleukin 18; KIM-1, Kidney Injury Molecule-1; 
L-FABP, Liver-type Fatty Acid-Binding Protein; NGAL, Neutrophil Gelatinase-Associated Lipocalin; RBF, renal blood flow; 
UP, ureteral pressure.
Phase
Acute phase 
(1-2 hours)
⬆RBF to compensate ⬆ UP  
keeping ≈ GFR
Mid phase 
(2-5 hours)
Later phase 
(>5-24 hours)
⬇ RBF ⬇ GFR⬆ UP
⬇ RBF ⬇ GFR⬆/ ≈ UP
Chronic phase 
(>24 hours)
⬆RBF to compensate ⬆ UP  
but GFR ⬇
⬇ RBF ⬇ GFR
⬇ RBF ⬇ GFR
NGAL, KIM-1, IL-18, 
L-FABP
Creatinine, Urea, Cys C
Time of 
expression of AKI 
marker
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Animal models creating partial ureteral obstruction have found evidence of parenchymal 
loss, peripelvic and interstitial fibrosis in the early phase (2-4 weeks) of unilateral 
obstruction (Botto, 2011; Guerin, 2008). These findings show the deleterious impact on 
long-term renal obstruction, even in models with incomplete obstruction. Interestingly the 
degree of tissue damage did not always correlate with the grade of dilatation of the upper 
tract. For these reasons, we believe that we should not rely only on the presence or 
absence of hydronephrosis in the imaging studies of patients with stone disease to rule 
out the existence of subclinical kidney injury.  
Many research studies have focused on analyzing mechanisms to avoid apoptosis and 
fibrosis in animal models with renal obstruction. Nitric oxide (NO), transforming growth 
factor (TGF-β1), Tumoral Necrosis Factor-α (TNF-α) and other new biomarkers have 
been implicated in renal remodeling. Some of these will be later discussed because their 
expression during episodes of ischemia/obstruction has been used to identify patients 
with a higher risk of poor outcomes, and are the current basis for timely AKI diagnosis. 
1.3 Mechanisms of renal injury 
Urinary obstruction causes a significant derangement in the mechanisms of urinary 
concentration, and continuous obstruction causes cellular injury leading to tubular and 
interstitial atrophy, fibrosis and cellular proliferation (Ito, 2004). Apoptosis is the main 
pathway that leads to renal atrophy and chronic kidney disease (CKD), which is 
principally established by glomerular sclerosis and interstitial fibrosis.  
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Apoptosis is orchestrated by several intracellular and transmembrane signals involving 
caspase enzymes and TNF-α pathway resulting in the release of intracellular proteins 
with subsequent tubular cell death (Chevalier, 2009). Renal architecture is also affected 
when acute inflammation augments the synthesis of metalloproteinases leading to fibrotic 
changes. 
The angiotensin pathway is a promoter of fibrotic changes by upregulating the expression 
of cytokines that stimulate extracellular inflammation, such as TNF-α and TGF-β1. The 
synthesis of extracellular matrix, mostly collagen fibers, and the signaling process to 
recruit inflammatory cells contributes to the histological changes that decrease the 
amount of parenchyma by destruction of the nephrons (Hewitson, 2009). Tubular atrophy 
and interstitial remodeling also cause obliteration of postglomerular peritubular 
capillaries, with a subsequent decrease in the GFR (Ito, 2004).  
A similar biological pathway of renal fibrosis linked to ischemic injury is also exhibited 
in cases of chronic obstruction. The interactions between inflammatory cells and 
interstitial cells, besides causing fibrosis in tubular area, can cause de-differentiation into 
mesenchymal cells or apoptosis of endothelial cells leading to renal ischemia (Chevalier, 
2009). This process may be slow, but may explain the progressive kidney damage seen in 
patients with chronic UUO. 
As urologists we are interested in the grade and time course of obstruction because these 
factors will impact the histological injury of the renal parenchyma and the long term 
global renal function.  Kerr in 1956 was the first to correlate the degree of injury with the 
duration of obstruction. Vaughan evaluated the radiological and pathological appearance 
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of unilateral obstructed renal units in dogs and found a remarkable recovery 4 weeks after 
relieving the obstruction. In contrast, animals that had an obstruction longer than 7 weeks 
however, did not have complete recovery (Kerr, 1956; Vaughan, 1971). 
The extent and magnitude of the obstructive process and the degree of cell loss during the 
inflammatory and fibrotic post-obstructive process play important roles in the recovery of 
renal function. The duration of unilateral ureteral obstruction and the animal species 
analyzed have been found to be determinants of renal recovery (Bander, 1985; Leahy, 
1989; Vaughan 1973). Other factors such as level of obstruction, compliance of 
collecting system, presence of infection, and integrity of lymphatic channels may affect 
the final pathway for histological injury (Vaughan, 2004). 
Upon relief of obstruction, not all of the mechanisms behind kidney injury will halt. 
Progression of renal damage has been demonstrated in histological analysis in a rat study 
after only 3 days of complete ureteral obstruction, despite normal renal blood flow or 
GFR (Ito, 2004). Cochrane and colleagues developed a mouse model where UUO was 
carried out for 10 days, and then were allowed to recover for a period of 1, 2, 4 or 6 
weeks. Results showed a significant increase in the number of macrophages and collagen 
fibers during the first weeks after obstruction relief with a decrease in the unilateral GFR, 
however, animals that were sacrificed after 6 weeks had a decreased grade of fibrosis and 
inflammation, but the eGFR of the affected unit was between 50-84% of the contralateral 
side (Cochrane, 2005). This definitely may compromise the long-term renal function, 
especially if we translate these findings to patients with medical conditions that 
chronically affect renal function, like diabetes, hypertension or recurrent stone disease.  
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The process of renal obstruction, either unilateral or bilateral, involves vascular, 
hemodynamic, and humoral pathways which are intended to respond to the insult, 
however these same complex mechanisms of renal restoration may contribute to 
architectural alterations that accelerate nephron loss and subsequent CKD (Harrison, 
2015).  
1.4 Acute Kidney Injury  
Acute kidney injury (AKI) is a broad term used to define a sudden decrease in the GFR of 
both kidneys causing retention of waste products, such as urea and creatinine and 
dysregulation of extracellular volume and electrolytes (Bellomo, 2012; Palevsky, 2014).  
While this condition might be subclinical and may not be recognized by a medical 
practitioner in asymptomatic patients with normal baseline renal function, alternatively it 
might be life-threatening and considered as a risk factor for patient mortality in an acute 
illness, like septic shock. The duration, severity, and baseline renal function will 
determine if other metabolic anomalies will accompany the scenario. Recently, the term 
AKI replaced the expression “acute kidney failure”, with the latter now reserved only for 
severe kidney injury associated with the need for renal replacement therapy, such as 
hemodialysis. AKI can be caused by three different mechanisms, which will be explained 
below, and Figure 4 shows the most common causes of each.  
• Prerenal, refers to the clinical situation where the glomerular filtration mechanisms 
are preserved and the dysfunction arises from a hypovolemic state, or renal blood 
flow is reduced. Clinical examples include patients with AKI related to extensive 
bleeding or septic patients where decreased vascular resistances diminish the renal 
blood flow, and patients with cardiogenic shock. The physiological response to renal 
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hypoperfusion involves vasodilation of the afferent arteriole and vasoconstriction of 
the efferent arteriole in an attempt to keep an adequate blood flow for GF. If the renal 
hypoperfusion is not reversed, ischemic insult to the tubules will occur which is 
called Acute Tubular Necrosis (ATN). 
• Renal causes of AKI are the most common and involve a primary dysfunction within 
the nephron. ATN is by far the most frequent cause of AKI in the emergency 
department, being intimately related to prerenal disturbances, but some intrinsic and 
extrinsic toxins and exogenous agents may cause direct tubular damage (i.e. 
cisplatin, non steroidal anti-inflammatory drugs) 
• Postrenal causes are of particular interest to urologists because an appropriate and 
timely treatment can prevent serious complications. These are related to acute 
obstruction of the urinary system; and as previously explained the severity is 
associated to the time of onset and bilateralism.  
	
Figure 4: Common causes of AKI according to the specific cause. 
Acute Kidney 
Injury - AKI
Postrenal
Renal
Prerenal
§ Hypovolemic shock –
hemorrhage
§ Congestive heart failure
§ Acute occlusion of renal artery
§ Acute glomerulonephritis
§ Interstitial nephritis
§ Acute tubular necrosis
§ Vasculitis
§ Upper urinary tract obstruction
§ Bladder-outlet obstruction
 16 
1.4.1 Definition and diagnosis 
Different groups have defined AKI, and distinct classifications have been developed to 
improve the threshold of detection and the quality of health care. The most common 
schemes are the Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) and Acute 
Kidney Injury Network (AKIN) criteria. Definitions are similar and are based on 
creatinine levels, urine output and preferably require knowledge of baseline serum 
creatinine of the patients (Bellomo, 2004; Mehta, 2007). 
AKI is a diagnosis commonly encountered in the emergency department and the 
Intensive Care Unit, with prevalence rates as high as 50-60% (Bouchard, 2015). Patients 
with AKI usually present clinical manifestations from other systems associated with an 
underlying disease. Diagnosis of AKI is made after biochemical test are ordered, such as 
serum blood nitrogen urea and creatinine, or clinically by measuring the urine output. 
Both parameters are functional and do not reflect the histological renal injury.  
The RIFLE criteria, proposed by the ADQI group (Acute Dialysis Quality Initiative), 
graded renal injury in three levels and determined two different outcomes accordingly. It 
uses the serum levels of creatinine or the urine output of patients over time to grade the 
level of injury (Bellomo, 2004). The AKIN criteria is also commonly used in the acute 
setting and employs similar parameters as the RIFLE classification, but addresses only 
one outcome, the need for renal replacement therapy (Mehta, 2007). As Figure 5 
demonstrates, RIFLE definitions depend on a proportional increase of serum creatinine or 
oliguria for more than 6 hours. AKIN also defines Stage 1 injury as an increase creatinine 
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of  ≥ 0.3 mg/dl. These definitions obviously do not fit all cases and reveal the need for 
more specific and practical markers of kidney injury.  
 
Figure 5: RIFLE and AKIN criteria of acute kidney injury (Adapted from Bellomo, 
2004 and Mehta, 2007). 
 
Serum Creatinine 
Creatinine (Cr) has been considered the gold standard for global kidney function 
evaluation. The absolute value might be affected by the rate of production, the hydration 
status of the patient and the type of creatinine assay. Moreover, abnormal serum levels 
are only observed when more than 50% of the glomerular filtration rate is affected. In 
unilateral kidney injury in the presence of a normal contralateral unit, creatinine may not 
be elevated at all. One other important drawback of serum creatinine measurement is the 
RIFLE Criteria
Risk UO < 0.5 ml/kg/hr (6 hrs)
Injury
Failure
⬆Cr x 2,
eGFR decreases > 50%
⬆Cr x 3,
eGFR decreases > 75%,
Cr ≥ 4 mg/dl
Loss
End-
Stage
Complete loss of renal function for > 4 weeks
⬆Cr x 1.5,
eGFR decreases > 25%
UO < 0.5 ml/kg/hr (12 hrs)
UO < 0.3 ml/kg/hr (24 hrs) 
Anuria x 12 hrs
End Stage Renal Disease > 3 months
AKIN Criteria
Stage 1UO < 0.5 ml/kg/hr (6 hrs)
Stage 2
Stage 3
⬆Cr x 2
⬆Cr x 3,
Cr ≥ 4 mg/dl with ⬆≥ 0.5 
mg/dl
Loss
End-
Stage
Patients requiring Renal Replacement Therapy are 
considered to have met Stage 3 
⬆Cr x 1.5,⬆ ≥ 0.3 mg/dl in Cr 
UO < 0.5 ml/kg/hr (12 hrs)
UO < 0.3 ml/kg/hr (24 hrs) 
Anuria x 12 hrs
End Stage Renal Disease > 3 months
Abbreviations: Cr, Creatinine; eGFR, estimated glomerular filtration rate; UO, urine output.
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need for a baseline value to compare with and to define AKI according to the appropriate 
classification. Because it can take more than 24-48 hours to increase in the setting of AKI 
it loses the diagnostic performance when there is a sudden change in the eGFR. In 
summary, by using serum creatinine as a marker of AKI we are delaying the diagnosis by 
identifying the functional consequence of the kidney damage, and not the injury by itself.  
Cystatin C 
Cystatin is a protease inhibitor produced by almost all human cells in a constant rate, it is 
filtered by the glomerular membrane and seems to be unaffected by factors other than the 
GFR. It has been proposed as an alternative option from serum creatinine to assess renal 
function and predict mortality and cardiovascular events. Several population-based 
studies have evaluated its role in the detection and prognosis of CKD finding a good 
association with the eGFR and better predictive rates for ESRD and survival than serum 
creatinine (Ingelfinger, 2013; Shlipak, 2013). Cystatin C has also been useful to detect 
subclinical AKI in different cohorts of ICU patients (Gaygisiz, 2016) but its role in 
urological patients has been inconsistent, and it has not been associated with 
hydronephrosis (Karakus, 2016; Madsen, 2012). Moreover, it may reflect a functional 
consequence of the renal damage, instead of a true injury. 
Urine output 
Low urine output, also called oliguria (< 0.5 ml/kg/hr) is considered a diagnostic 
parameter for AKI diagnosis (Figure 5), and can also be monitored to evaluate the 
patient’s response to therapeutic maneuvers. Change in urine output is one of the first 
signs of kidney injury and it appears even before biochemical changes. Prerenal causes of 
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AKI are characterized by anuria or oliguria, while urine output in renal and postrenal 
situations vary from anuria to polyuria.  
Several observations have been raised about the clinical utility of these definitions and 
the need of individualization in specific situations. The current recommendation is to use 
the first available serum creatinine and avoid using a historical value (Fliser, 2012). Other 
authors suggest the use of urine output by ideal body weight. These limitations come 
from the absence of evidence regarding the ideal cut-off value to determine the different 
stages of AKI, independently of the criteria used.  
New evidence suggests that, these criteria may be replaced by biomarkers of renal tubular 
injury, such as KIM-1 and NGAL (Siew, 2012). Until further evidence proves the 
positive clinical impact of these new methods, we will continue to use the 
aforementioned criteria to detect patients with kidney injury.  
Urine protein and urine protein-creatinine ratio 
Proteinuria is a well-defined effect of glomerular disease and has been used to determine 
and monitor the grade of injury in different clinical situations. It may reflect a decreased 
capacity of reabsorption at the level of renal tubules, implicating tubular or interstitial 
damage, but an increased protein production by systemic disease (e.g. multiple myeloma) 
can also cause proteinuria by an overflow mechanism. This parameter is recommended 
for detecting and monitoring proteinuria in patients with CKD, but it not the best strategy 
to evaluate AKI because it directly relies on creatinine excretion, which is usually 
diminished in patients with AKI (Nguyen, 2009).  
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1.4.2 Post renal causes of AKI 
Urological patients with AKI are seen in less than 10% of the hospitalized cases, but the 
prompt diagnosis with early relief of obstruction in these patients can prevent lifelong 
kidney damage (Caddeo, 2013). Table 1 already described the most common causes 
associated with upper urinary tract obstruction. As urologists we face AKI in patients 
with bilateral hydronephrosis, most commonly caused by bladder outlet obstruction or 
bilateral obstructive stone disease. On the other hand, unilateral hydronephrosis is usually 
not accompanied by AKI, except in patients with chronic kidney disease or with a non-
functioning contralateral renal unit. Despite this, the obstructive process may initiate the 
cascade of metabolic mechanisms that could lead to renal fibrosis.  
As previously discussed, UUO is also associated with the initiation of injury mechanisms 
that lead to fibrosis, cellular apoptosis and chronic kidney damage. The usual clinical 
parameters of kidney function are insufficient to detect unilateral kidney damage in 
patients with a contralateral normal kidney.  
We focused our research on the evaluation of AKI markers in patients with stone disease 
and hydronephrosis. We planned to also include patients with UPJO, which is a specific 
condition of upper urinary tract obstruction that is usually not associated with other 
inflammatory conditions.  
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1.4.2.1 Renal stone disease 
Nephrolithiasis is one of the most common urological causes of emergency department 
visits; patients usually seek medical evaluation after an episode of renal colic. Initial 
evaluation is performed to determine the diagnosis, and imaging studies are completed to 
define the appropriate management, which depends on the clinical manifestations, 
association with infectious processes, and comorbid conditions. Several studies have 
shown an increased risk of CKD and ESRD in patients with nephrolithiasis (Keddis, 
2013). 
Patients requiring urgent management usually have a double J stent or nephrostomy 
placed after being evaluated in the emergency department. Those without an urgent 
indication for treatment, despite the grade of obstruction, are seen in an outpatient basis 
to determine the need for further management. Patients with small ureteric stones 
(<7mm) may be offered medical expulsive therapy to promote the passage of the calculus 
avoiding an invasive procedure (Miller, 2007; Nakada, 2015). Approximately 15-20% of 
the patients require an invasive management, either emergent decompression of the 
urinary tract or definitive therapy: shockwave lithotripsy (SWL), ureteroscopy (URS) and 
percutaneous nephrolithotomy (PCNL) (Nakada, 2007). 
Specific indications for stone management are described in the literature (Preminger 
2007; Türk, 2015), and are beyond the scope of this study, but to summarize, large kidney 
stones (usually > 2cm) are treated with PCNL, smaller kidney stones and ureteric calculi 
required SWL or URS. For the purpose of this study, we did not evaluate patients who 
had SWL because several studies have found an increase expression of AKI markers 
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during this treatment, which is related to injury of the renal parenchyma and might affect 
the interpretation of our results (Nader, 2013; Nikoobakht, 2006). 
1.4.2.2 Ureteropelvic junction obstruction and ureteric 
stricture 
Ureteropelvic junction obstruction (UPJO) is a urological disease encountered in the 
pediatric and adult populations characterized by a congenital anatomical anomaly that 
impairs the flow of urine from the renal pelvis to the proximal ureter. The obstruction 
results from an aperistaltic segment of ureter or the presence of abnormal blood vessels 
that cause extrinsic compression of the upper ureter. Imaging studies usually reveal a 
severely dilated renal pelvis with an abrupt transition to a normal size upper ureter. Some 
patients may have secondary renal calculi associated with long-standing obstruction, 
although these stones are typically not the cause of obstruction. 
Regardless of the cause and the age at the time of diagnosis, the clinical assessment 
should determine if the mechanical obstruction affects the dynamic flow of urine to the 
lower urinary tract, which means there is a functional repercussion to the renal unit. A 
diuretic renal scan is considered the gold standard to determine the presence of functional 
obstruction. A flat curve and a clearance half-life of the radiotracer > 20 minutes in the 
renography scan is considered diagnostic of a functional UPJO (Khan, 2014). Treatment 
of UPJO is warranted to relief symptomatic episodes of pain, infection but mostly to 
avoid further deterioration of the renal function. The best treatment option is a minimally 
invasive pyeloplasty, performed by either a laparoscopic or robotic approach and it is 
associated with a success rates greater than 90% (Khan, 2014). Equivocal cases with 
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radiotracer half-life of 10-19 minutes were not historically considered to have functional 
obstruction, and clinical observation was warranted. Recent literature suggests that 
pyeloplasty provides adequate functional results (Ozayar, 2015). Postoperative follow-up 
includes a diuretic renal scan to evaluate the split renal function and rule out restenosis of 
the recently created ureteropelvic anastomosis. 
Patients with hydronephrosis caused by nephrolithiasis or UPJO obstruction are ideal 
candidates to evaluate the impact of urinary tract obstruction on urinary AKI markers 
levels. They have preoperative radiological evaluation, which is used to plan the 
intervention and to determine the presence and grade of hydronephrosis. Renal function 
assessment is always made during the initial evaluation at the initial urological 
consultation. An invasive procedure is performed (URS/PCNL/pyeloplasty) to remove 
the cause of obstruction and follow-up studies determine the success of the intervention. 
The standard of care will allow the collection of urine samples and correlate clinical, 
radiological and biochemical findings with the levels of these markers in this set of 
urological patients.  
1.5 Diuretic renography 
Diuretic renography is a nuclear non-invasive study which provides a measurement of the 
renal function in each of the renal units, while detecting the presence of obstruction in the 
upper urinary tract. This test allows discrimination of the urinary tract system dilation 
without obstruction, from true physiological obstruction. It is based on the principle that 
the injected radiotracer in freely filtered and accumulated in the renal collecting system, 
and in the absence of urinary tract obstruction the diuretic increases the urine flow 
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clearing the tracer from the renal silhouette. Tracer activity along with time are plotted in 
a X-Y graph (Time-activity curve), which is visually evaluated with the aid of 
computerized software to determine the clearance half-time of the radiotracer, less ten 
minutes is considered normal.  Several factors may play an important role in obtaining 
and interpreting the results, like hydration status, administrated diuretic dose and time, 
previously determined region of interest (ROI) and the method of evaluation 
(computerized vs visual) (Karam, 2003; Sarkar, 1992). 
In clinical practice, a half-life clearance > 20 minutes after the diuretic dose is considered 
diagnostic for obstruction. Depending of the site and cause of obstruction, appropriate 
management should be tailored according to patient’s conditions. However, some patients 
show clinical signs and symptoms of chronic obstruction with a diuretic renogram that 
fails to show obstruction (1/2 life clearance 10-20 minutes). There is no agreement about 
the most appropriate treatment, being observation, temporal stent placement or surgery 
accepted management strategies. Despite that current treatment indications are based on 
the renogram findings of obstruction, there is recent evidence that patients with equivocal 
UPJO may benefit from minimally-invasive treatment, by preserving long term renal 
function (Ozayar, 2015). This is also another argument that reflects that our current 
methods for urinary tract obstruction diagnosis are not 100% accurate, and need to be 
revised to improve patients’ health care.  
1.6 Markers of Acute Kidney Injury 
Since it was first introduced, over 80 years ago, creatinine has been considered as an 
accurate parameter to determine global renal function. Despite its widespread use, 
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creatinine is considered a poorly sensitive marker in the acute setting, mainly because it 
may take 48-72 hours after the renal injury for serum levels to rise. It is usually measured 
in conjunction with serum urea, which accumulates in the blood stream due to ineffective 
glomerular function.  
Both serum parameters do not reflect the renal damage in “real time”. Glomerular 
filtration needs to decrease to more than 40-50% to show increments in baseline levels, 
making them insensitive for detection of acute kidney injury (Siew, 2011). Moreover, 
slight injury to renal parenchyma, which may be presented in cases of incomplete or 
unilateral obstruction, may not be detected by these standard tests.  
Despite the improvements in the management of acutely ill patients, the mortality and 
morbidity associated with AKI has not decreased during the last two decades (Chertow, 
2005). One of the main reasons is that serum creatinine reflects renal function but not 
real-time damage (Nguyen, 2007: McWilliams, 2014). Contrary to what has happened in 
myocardial infarction, where troponins are very sensitive indicators of abnormal 
myocardial perfusion making earlier interventions effective to improve patients’ 
outcomes, the diagnosis of AKI is delayed by the use of serum creatinine. This 
shortcoming with serum creatinine has stimulated research into identifying more accurate 
markers of renal function (Siew, 2011). 
Recently, some translational research reports suggested the promising role of proteins 
that are upregulated after kidney injury (Bonventre, 2014). Initially, animal experiments 
revealed good specificity and sensitivity of these molecules to detect renal damage after 
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ischemic or nephrotoxic insult (Siew, 2011), and human cohort studies have evaluated the 
diagnostic performance of several biomarkers in AKI and CKD (Hsu, 2015).  
In fact, the American Society of Nephrology designated AKI biomarkers research as a 
top priority, leading to the identification of at least 20 different potential markers. A 
biomarker is a specific feature that can be measured and indicates a biological process 
(Atkinson, 2001). According to several studies and expert opinion, the most promising 
are NGAL, KIM-1, Interleukin-18 (IL-18), cystatin-C, liver-type fatty acid-binding 
protein (L-FABP), glutation S-transferase (GST) and N-acetyl-B-D-glucosaminidase 
(NAG). Clinical studies have analyzed their particular role in predicting outcomes of 
critically ill patients (Zappitelli, 2007), risk of AKI in patients after cardiac surgery 
(Perrotti, 2015), chronic renal injury in diabetic patients (Sabbisetti, 2014), contrast-
induced nephropathy (Tong, 2015), and renal transplant patients with graft dysfunction 
(Alachkar, 2011; Malyszko, 2010). 
These proteins are now considered as biomarkers of AKI; they can be measured in blood 
and urine and have shown a better correlation with the effects of AKI than serum 
creatinine (Siew, 2011). The detection of these molecules relies in three different 
mechanisms that may provide signs of renal injury in an opportune fashion, showing 
more sensitivity to AKI than serum creatinine: 
• Structural proteins excreted during initial tubular damage 
• Molecules not reabsorbed after tubular dysfunction 
• Protein production after specific genes are upregulated during acute tubular injury 
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The third mechanism has been studied the most, with KIM-1 and NGAL as the more 
commonly evaluated biomarkers in basic and clinical studies (Cost, 2013; Karakus, 2016, 
Urbschat, 2014).   
Multiple questions are still remaining, specifically about the clinical usefulness of these 
proteins, especially in urological patients. For example, KIM-1 has been catalogued as a 
marker of injury, but also some evidence exists in animal studies about a possible anti-
inflammatory effect (Yang, 2015). On the other hand, NGAL can also be secreted by 
activated neutrophils, which may reduce the sensibility for AKI detection in patients with 
inflammatory conditions, other questions include: 
• Is the renal obstruction associated with subclinical acute kidney injury? 	
• Does the hydronephrosis grade correlate with the extent of renal injury measurable by 
AKI markers? 	
• Are any of these proteins a reliable marker of hydronephrosis?	
• Can we use these biomarkers in urological patients to assess other systemic 
conditions that may cause renal injury?	
McWilliam and colleagues reported the reference intervals for KIM-1 and NGAL in 
healthy children analyzing more than 250 samples from UK and USA being an essential 
step for further use of these biomarkers in clinical settings, such investigations have not 
been performed in adult populations (McWilliam, 2014). In order to control the variations 
in hydration status and urine production, urinary biomarkers are usually normalized to the 
urinary levels of creatinine.  
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Our research was centered in the evaluation of KIM-1 and NGAL, which can be 
measured in urine, and are mostly expressed in renal tissue. We will present a summary 
of the most important information related to these two biomarkers. 
1.6.1 KIM-1 
Initially named TIM-1(Tissue Injury Molecule-1), this marker was identified using 
mRNA analysis after renal ischemic injury in rats. It is a transmembrane protein 
expressed in small amounts in normal kidney, but highly replicated in the proximal 
tubular epithelial cells after an ischemic insult, having a potential role in the regeneration 
of the normal function of the tubular cells (Ichimura, 1998). Recently, Yang and 
colleagues proposed an antiinflammatory effect by enhancing the phagocytic process and 
protecting the kidney from AKI (Yang, 2016).  
KIM-1 has a immunoglobulin-like domain, specifically located in the apical membrane of 
proximal tubular cells. Histological analysis has revealed a predisposition for expression 
in the proximal renal tubule. The ectodomain is stable and appers in the urine after renal 
insult. It has been qualified by the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA) for preclinical assessment of nephrotoxicity 
(Bonventre, 2014; Dieterle, 2010). 
Several theories have been evaluated in recent years to elucidate the overexpression of 
KIM-1 after renal injury. Because it is highly expressed in tubular epithelium after cell 
injury, KIM-1 may play a role in the regeneration of epithelial cells by facilitating their 
restoration, but other studies have shown that KIM-1 has a renoprotective effect, by 
 29 
facilitating the apoptotic response of injuried cells (Bonventre, 2014). Despite the 
evidence regarding the possible protective effect of KIM-1, chronically injured cells also 
express KIM-1 on their surface augmenting the interstitial fibrotic process, Whether the 
expression is mainly affected by acute or chronic injury, a consensus exists regarding the 
limited expression in healthy kidney tissue. 
Animal studies have demonstrated an increased expression of urinary KIM-1 after renal 
insult. A rat model experiment found an increased expression of tissue and urinary KIM-
1 in animals after cisplatin-induced nephrotoxicity; it was the most sensitive marker, 
correlated with the progression of kidney lesion and was observed before histological 
injury (Vinken, 2012). Vaidya and colleagues found a significant increment in urinary 
KIM-1 levels after bilateral renal ischemic injury in rats, while serum creatinine remained 
within normal limits (Vaidya, 2009). 
Several clinical studies have demonstrated the relationship between KIM-1 expression 
and chronic and acute kidney injury. It has been found to be a good predictor of 
postoperative AKI in patients undergoing cardiac surgery, even before serum creatinine 
elevation (Han, 2009). Sabbisetti and collegues found that elevated serum KIM-1 levels 
predicted the rate of eGFR and the risk of developing ESRD in Type 1 diabetic patients 
(Sabbisetti, 2014).  
Our Urology department investigated the expression of KIM-1 after shockwave 
lithotripsy in kidney stone patients. We demonstrated higher urinary KIM-1 levels in 
stone disease patients compared to healthy subjects, and we noted a significant increment 
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in the urinary levels hours after the lithotripsy suggesting transient renal tissue injury 
caused by the SWL (Nader, 2013). 
Some case-control studies have found elevated urinary levels of KIM-1 in patients with 
obstructive nephropathy compared to controls. Wasilewska and collegues compared 
pediatric patients with UPJO to patients with mild hydronephrosis and healthy children  
and found higher preoperative KIM-1 levels in those with UPJO, decreasing up to 75% 
three months after the pyeloplasty (Wasilewska, 2011). Another study from China, 
evaluate the expression of KIM-1 and NGAL in patients with AKI and obstructive 
nephropathy and found a good predictive value to diagnose AKI, furthermore the same 
group demonstrated that postoperative levels of these markers were predictors of renal 
function at one year measured by serum cretininea, albeit radiological information was 
missing and patients had severely impared renal function (Xie, 2014; Xue, 2014).  
1.6.2 NGAL 
Neutrophil gelatinase-associated lipocalin (NGAL, lipocalin 2) is a 178-aminoacid 
polypeptide chain which belongs to the lipocalin superfamily, and was originally isolated 
from neutrophils (Kjeldse, 1993). Different molecular forms have been described and will 
be discussed later, but several clinical studies have concluded it is a sensitive biomarker 
of AKI (Mårtensson, 2014). Most of the information regarding the origin and 
biochemical role comes from animal studies, and several theories have been created to 
explain its function after renal injury.  
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Zappitelli and collegues found urinary NGAL to be useful marker of AKI severity in 
critically-ill children (Zappitelli, 2007). Kuwabara investigated urinary and serum 
expression of NGAL in mice with obstructive nephropathy. Unilateral ureteral 
obstruction causes a 100-fold increment in NGAL synthesis in distal nephrons, which 
suggests damage to tubular epithelia (Kuwabara, 2009). Other AKI studies have 
confirmed the increased synthesis in tubular epithelia, but models of chronic injury have 
found that urinary NGAL also correlates with the eGFR.  
NGAL is not only secreted in renal tissue, it has also been isolated in hepatocytes and 
immune cells, being involved as part of the innate response against gram-negative 
bacteria. In fact, it was initially discovered in the immune response during bacterial 
infections, because it binds to siderophores for iron transport and prevents the growth of 
bacteria dependant on iron supply. Xu and collegues compared NGAL levels in patients 
during an acute bacterial or viral infection and found a positive correlation of its levels 
with a bacterial infection (Xu, 1995). Genetically modified mice lacking both NGAL 
gene copies have been found to have an increase risk in Escherichia coli infections 
(Berger, 2006), and a recent small clinical study demonstrated that pediatric patients with 
recurrent UTI have decreased urinary NGAL levels compared to patients without 
recurrent UTI (Forster, 2014). Recent studies have address the prognostic value of plasma 
NGAL (Total NGAL) as a marker of systemic inflammatory response symptoms (SIRS) 
and sepsis, it was found as a predictor of mortality and multiple organ dysfunction 
(Wang, 2015). NGAL has been evaluated after renal ischemic injury: van den Akker et al 
found that serum NGAL was a good predctor of delay graft function after kidney 
transplantation. A small prospective cohort study patients undergoing partial 
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nephrectomy failed to show postoperative urinary NGAL as a predictor factor of renal 
injury (Sprenkle, 2013; van den Akker, 2015). Whether NGAL is most specific as a 
marker of systemic inflammatoion or renal injury remains unanswered (Martensson, 
2014).  
Differences in the expression of NGAL in several clinical situations are explained by the 
presence of different molecular forms of NGAL in urine and plasma. Cai et al analyzed 
urine samples of patients after cardiac surgery, patients with UTI and in incubated HK-2 
(human kidney epithelial) cells by using Western blot analysis they determined the origin 
of the 3 molecular NGAL forms (Cai, 2009). The 21-25-kD monomer was primary 
secreted by HK-2 cells and to some extent by the activated neutrophils, and may reflect 
the severity of tubulointestitial damage (Nickolas, 2012). The 45-kD disulfide-linked 
homodimer was secreted by neuthrophils and the 135-kD heterodimeric, conjugated with 
gelatinase, also secreted by ephitelial cells, found in small quantities only (Glassford, 
2013; Nickolas, 2012).  
Their findings were supported by the discovery of elevated levels of urinary Monomeric 
NGAL in patients with AKI after cardiac surgery, while patients with UTI, exhibited an 
increased level of the dimeric form. Authors also found differences in the specificity of 
the antibody epitope of both forms, which was used to develop specific essays for each 
molecular form.  
The vast majority of published studies about NGAL include the use of essays with some 
kind of cross-reaction between the monomeric and homodimeric form. This could explain 
the differences in clinical performance of the test, and the contradictory results. 
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Moreover, multiple studies about AKI excluded patients with conditions that may 
interfere with the expression of this marker, such as stone disease. For example, 
Holzscheiter confirmed the role of NGAL as a promising tool to detect tubular injury but 
it was influenced by the grade of leukocyturia (Holzscheiter, 2014).  
Nickolas and collegues evaluated the relationship between urinary Monomeric NGAL 
measured by immunoblot and the histological evidence of tubulo-intestitial damage in 
patients with CKD. Their findings support the theory that Monomeric NGAL reflects 
tubular damage. They found a higher correlation with tubular athrophy and intestitial 
fibrosis, although Monomeric NGAL did not correalted with leukocyte infiltrate or 
mesangial proliferation, suggesting a better association with chronic rather than acute 
processes (Nickolas, 2012).  
Mårtensson and colleagues were able to characterize the expression of Monomeric 
NGAL by renal epithelial cells from the homodimeric form secreted by neutrophils using 
two different ELISA assays (Mårtensson, 2012). Recently, a human monomeric-specific 
NGAL ELISA kit was made commercially available (Bioporto, Hellerup, Denmark), and 
showed <1% cross-reactivity with the homodimer form. This test improves the ability to 
detect Monomeric NGAL, which in the absence of inflammatory conditions could be 
mainly released by renal tubular cells (Bangert, 2012).  
1.6.3 Other biomarkers  
Some other molecules have been investigated in basic and translation research as 
potential markers of kidney injury. Animal and human studies have shown contradictory 
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results regarding the expression of cystatin, B2-microglobulin, interleukin-18, 
osteopontin and liver-type fatty acid-binding protein (L-FABP). We therefore elected to 
study the two markers showing most promise, KIM-1 and NGAL.  
Despite the recent investigations, there was a need to prospectively evaluate the role of 
these markers in urological patients with urinary tract obstruction and analyze their 
expression considering the grade of obstruction and the presence of inflammatory 
conditions, such as stone disease or ureteric stents. Similarly, the use of a novel assay to 
determine the specific expression of Monomeric NGAL might aid in the evaluation of 
AKI in urological patients who usually suffer inflammatory conditions in the urinary tract 
that may affect the levels of  NGAL. We believe our study will provide sufficient 
information to determine if these molecules are useful in the evaluation of urological 
patients.  
1.7 Hydronephrosis 
The term hydronephrosis is an anatomical denomination commonly used to describe 
dilatation of the renal pelvis and/or calyces (Cho, 2007; Ito, 2010). Hydronephrosis is not 
a synonym of obstruction, but is usually associated with it, except in cases of 
vesicoureteral reflux, congenital megaureter or in patients with acute pyelonephritis 
accompanied by a non-peristaltic ureter, as we previously discussed. It is a radiological 
diagnosis, usually made after a renal ultrasound or a CT scan. In clinical practice it is 
commonly accepted that the grade of hydronephrosis correlates with the grade of 
obstruction, although this is just a supposition, because diuretic renogram is required to 
determine the presence and grade of obstruction.  
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The most acknowledged classification for hydronephrosis comes from the Society of 
Fetal Ultrasound (SFU), which uses coronal and axial views of abdominal ultrasound to 
assess the aspect of the renal parenchyma and the collecting systems (Fernbach, 1993). 
This classification has been generalized and used as standard for adult population studies. 
Cho and Ito described a similar hydronephrosis scale using CT findings in patients with 
upper urothelial carcinoma to predict aggressiveness of the disease (Cho, 2007; Ito, 
2010). The following table correlates both classifications:  
 
Table 2. Grading of hydronephrosis according to SFU and CT criteria (Adapted 
with permission from Fernbach, 1993, and Ito, 2011). 
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In clinical practice, and according to the treatment guidelines for stone disease, only the 
cases associated with septic processes and severe renal impairment are treated in an 
urgent fashion (Preminger, 2007; Türk, 2014). Most of the patients with stone disease and 
hydronephrosis have to wait weeks to months to receive definitive management. These 
patients have an increased risk to suffer “subclinical” renal injury, because creatinine 
levels are within normal limits, but the deleterious pathophysiologic process of 
obstruction lasts until the obstruction is mitigated.  
Another important factor that is difficult to extrapolate to clinical practice is the 
possibility of having a partial or a complete ureteral obstruction. The grade of 
hydronephrosis does not always correlate with the grade of obstruction. Several other 
factors play an important role, such as hydration status, split renal function, and time of 
onset. Complete obstruction of urine flow through the ureter might be accompanied by 
urine flow into venous or lymphatic systems. Whether this affects the pathophysiology of 
obstruction is not yet determined, but will probably be negligible.  
1.8 Charlson comorbidity index (CCI) 
The Charlson Comorbidity Index is a commonly used categorization that was described 
in 1987 to grade comorbid conditions, which may affect the mortality of the patients in 
longitudinal studies. It is widely used in the medical literature to evaluate the most 
significant comorbidities that may affect the expectancy of life of the patients. Initially 
included patient’s age and 19 different conditions, it was recently updated to include 23 
items that received a score, to predict the 10-year survival. CCI has been validated and 
accepted to describe patients’ comorbidities (Charlson, 1987; Charlson, 2008). We 
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planned using this index to determine and compare the baseline comorbidities of the 
patients.  
1.9 Purpose of the study 
This study will analyze the role of 3 AKI markers in urological patients: KIM-1, Total 
and Monomeric NGAL. To the best of our knowledge, there are no published studies 
describing the different isoforms of NGAL in urological patients. The main objective of 
our research is to determine the urinary levels of KIM-1, Total and Monomeric NGAL, 
before and after treatment in patients with urinary tract obstruction caused by intrinsic 
ureteral obstruction or stone disease. The results of this research may help design a 
larger multicenter study to assess the cost and time for diagnosis and follow-up of 
patients with hydronephrosis related to UPJO or stone disease. Additionally, we will be 
able to detect if patients with hydronephrosis due to obstruction and normal kidney 
function, according to serum creatinine, also have subclinical AKI as shown by an 
increase expression of urine markers.  
If we prove our hypotheses to be correct, urinary AKI biomarkers may aid in the 
diagnosis and discrimination of patients with obstruction (caused by stone or by UPJO) 
and kidney injury with the ease of a simple urine test. Our results may help reduce the 
reliance on imaging that is costly and may be associated with ionizing radiation 
exposure. Furthermore, overall results will provide information about the safety of 
delaying some interventions in patients with hydronephrosis without urinary tract 
obstruction. Moreover, a urine-based test that could be employed at the point of care 
might permit more timely intervention. These results may offer evidence regarding the 
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impact of stone disease on the urinary levels of AKI and might give useful information 
about the inclusion of urologic patients in large trials for AKI evaluation through 
urinary markers analysis.  
Our research project is intended and designed to evaluate the levels of the most 
commonly investigated urinary markers in patients with unilateral upper urinary tract 
obstruction. We expect to assess the following central hypothesis: 
a. Baseline urinary levels of KIM-1 and Monomeric NGAL will be statistically 
significantly higher in patients with unilateral renal obstruction caused by 
either the presence of a urinary stone or by an ureteric stricture compared to 
urinary levels after the treatment of obstruction. 
Secondary hypotheses to be considered are:  
a. KIM-1 and Monomeric NGAL will be statistically significantly different 
between patients with and without obstruction 
b. KIM-1 and Monomeric NGAL levels will be positively correlated with the 
the grade of hydronephrosis and the overall kidney function measured by the 
eGFR. 
c. Monomeric NGAL will have a better correlation with obstruction and renal 
function than Total NGAL 
We expect that patients with hydronephrosis due to obstruction will have higher levels of 
KIM-1 and Monomeric NGAL compared to healthy subjects and to patients with non-
obstructing stone disease.  
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Additionally, we plan to determine if patients with hydronephrosis and normal kidney 
function have subclinical AKI as shown by an increased expression of urinary 
biomarkers. If we prove our hypotheses to be correct, urinary AKI biomarkers may aid in 
the diagnosis and discrimination of patients with hydronephrosis as to the presence or 
absence of physiological obstruction with the ease of a simple urine test. These results 
may also provide evidence regarding the impact of stone disease in the urinary levels of 
AKI.  
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2 Study design 
This prospective cohort study was planned to observe the clinical course of patients with 
unilateral renal obstruction causing hydronephrosis due to stone disease or intrinsic 
ureteral disease, and to explore the expression of KIM-1, Total and Monomeric NGAL 
within the usual standard of care. We followed the STROBE (Strengthening the 
Reporting of Observational Studies in Epidemiology) guidelines (von Elm, 2008; 
Appendix 1) and the clinical study was approved by the Western University Health 
Science Research Ethics Board (Appendix 2).  
Our main objective was to determine the urinary levels of KIM-1 and NGAL (Total and 
Monomeric isoform), before and after treatment, in patients with hydronephrosis caused 
by intrinsic ureteral obstruction or stone disease. We chose these sets of patients for two 
reasons: Stone disease is the most common cause of upper urinary tract obstruction and 
affects many patients. Patients with intrinsic ureteral obstruction comprise a special 
situation where diagnosis and follow-up may be challenging with conventional imaging, 
and require the use of renography for diagnosis and follow-up.  The potential impact of 
our results could therefore be very relevant.  
Additionally, by including patients with obstruction without kidney stones and patients 
without obstruction and kidney stones we would know whether there are differences in 
the expression of Monomeric NGAL. Inflammatory conditions are thought to cause an 
increment in the Total NGAL concentration, but theoretically will not significantly affect 
Monomeric NGAL levels. We also aim to assess the expression of these markers in 
patients with stone disease and no hydronephrosis and in a healthy control group because 
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the medical literature does not have clear evidence about the pattern of expression of 
these proteins in these populations.  
All this information will allow a comprehensive evaluation about the clinical utility of 
these markers in urological patients. The study design will facilitate the evaluation of 
urinary marker expression in a longitudinal approach: when obstruction is present, and 
after the obstruction is relieved. Appropriate clinical and radiological follow-up will 
strengthen the results and several analyses will be performed to explore the role and the 
factors affecting the expression of these markers in urological patients.  
We have already stated that our primary focus will be to assess the expression of KIM-1 
and both Total and Monomeric NGAL in patients with hydronephrosis, but we also plan 
to analyze the differences in the expression of these urinary markers in patients with 
inflammatory stone disease and indwelling ureteric stents, where an inflammatory 
response may be present. We hypothesize that KIM-1 and Monomeric NGAL will be 
elevated in patients with hydronephrosis. We also hypothesize that these two markers 
would correlate to the grade of hydronephrosis and overall renal function. In order to 
complete the planned analyses, this cohort study investigated 3 different groups: 
1. Patients with hydronephrosis  
2. Patients with stone disease and no hydronephrosis 
3. Control group of subjects without stone disease or hydronephrosis 
Based on the standard of care in our urological practice, we were able to prospectively 
evaluate the concentration of urine markers in patients during their treatment and follow-
up. This gave us different patient populations that were evaluated independently and 
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compared among them longitudinally. Stone disease diagnosis and follow-up require 
imaging studies, such as Computed Tomography scan (CT scan) or a renal ultrasound 
which are usually performed as part of the standard of care by the treating urologists. 
This information was used to determine the presence or absence of hydronephrosis to 
include them in one of our 2 studied groups of patients and evaluate the stone 
characteristics.  
A preoperative urine sample was collected, along with two postoperative urine samples. 
Patients who required a double J stent placement during the surgical procedure, were 
followed during the two succeeding appointments to evaluate clinical and radiological 
parameters and collect urine samples. During the third visit, patients would no longer 
have a ureteric stent, and the levels of the urine markers should not be affected by the 
stent, but might be affected by the presence of residual stones.  
We anticipated that some patients with ureteral stones, while waiting for the surgical 
procedure could have spontaneously passed the stone. These patients were asked to give a 
second urine sample during the next clinic visit, after stone passage in order to complete 
the study. Likewise, in very selected cases, patients did not require ureteric stent 
placement after the surgical management of their stones and they completed the follow-
up after only one postoperative visit. 
The design of this study allowed a comparison of urine marker levels during the initial 
urological evaluation between two groups of patients and the control group. As there is 
some evidence suggesting a possible influence of inflammatory conditions on AKI 
markers expression, we decided to evaluate biomarker concentration using the third urine 
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sample, when patients do not have stents and the burden of residual stones is lower. 
Furthermore, we were able to explore if urinary markers expression correlates with the 
grade of leukocyturia. The following diagram illustrates the recruitment and flow of 
patients’ assessment along the study: 
 
Figure 6: Patient recruitment algorithm. 
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2.1 Sample size calculation 
No studies exist in the literature about the role and urine levels of Monomeric 
NGAL in urological patients. The information available came from trials performed 
in ICU (Intensive Care Unit) patients with sepsis and AKI. They used two different 
assays and reported median urinary concentrations of monomeric NGAL between 
145-350 ng/mL (Martesson, 2012; Bangert, 2013). This data cannot be used to 
calculate an appropriate sample size because our study involves patients in a 
different clinical scenario and who might have subclinical AKI, expecting lower 
biomarker levels. We propose an exploratory analysis for the Monomeric NGAL 
isoform, therefore the calculation was based on previous urological literature on 
KIM-1. 
As we previously discussed, literature about these biomarkers in urological patients 
is sparse, and only few studies longitudinally analyze KIM-1 urinary concentration 
in pediatric patients. According to previous data about the adjusted KIM-1 
concentration in urine from our centre (Fahmy, 2013), we were able to estimate a 
sample size (Wan, 2014). Using an α value of 0.05, with a power of 0.90 and a 
calculated effect size of 0.7, we needed 24 patients with hydronephrosis to detect a 
2-sided difference in KIM-1 levels  before and after the intervention. On the other 
hand, if we included 24 patients in each of the groups (hydronephrosis and no 
hydronephrosis) we will be able to detect a significant difference in KIM-1 levels 
between the two groups, with a power of 0.77, keeping an α value of 0.05.   
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A 1:2 ratio of control to study subjects will allow an adequate statistical analysis to 
compared the findings all groups of patients.  Clinical follow-up included 2 
postoperative visit, and we expected a possible 20-25% lost of follow-up, which is 
considered acceptable for this type of study (Kristman, 2004). We planned to recruit 
30 patients in each of the study groups to complete the calculated sample size. 
2.2 Recruitment and follow-up 
Exclusion and inclusion criteria were assessed after patients were clinically 
evaluated and the surgical treatment was decided during their Urology Clinic visit. 
The study was explained to potential candidates, which were invited to participate 
in our trial. Patients willing to participate signed appropriate documents according 
to out Ethics Board Committee guidelines (Consent Form/Letter of Information) 
and were asked to give a mid-stream urine sample (Appendix 3). 
Briefly, to be included in the “hydronephrosis group” patients needed to have 
unilateral ureteric stricture or unilateral stone disease, both associated with 
unilateral hydronephrosis, amenable to treatment by ureteroscopy, percutaneous 
nephrolithotomy or pyeloplasty. Patients recruited in the “no hydronephrosis 
group” needed to have imaging studies confirming the presence of unilateral stone 
disease in the absence of hydronephrosis, and requiring an endourological 
procedure as definitive stone treatment.  
All patients with active urinary tract infection, evidence of bilateral stone disease, 
preoperative presence of ureteric stent, use of indwelling bladder catheter or recent 
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history of sepsis were excluded from the study. Appendix 4 describes the specific 
details for each inclusion and exclusion group criteria. This study was conducted at 
St. Joseph Health Care (SJHC) London, and all recruited patients were required to 
have postoperative follow-up in our Urology Clinic.  
After patients agreed to participate, demographical, clinical, and radiological 
variables were evaluated from patients’ office charts and hospital electronic records 
to complete the data collection. It is the standard of practice that patients have a 
complete medical assessment the first time they visit the Urology Clinic, and these 
variables are evaluated by the treating urologist when discussing with the patient 
the best treatment option. The following table describes the variables evaluated at 
the first visit. 
 
Table 3. Evaluated baseline characteristics. 
Patients then went on to have their surgeries at SJHC, with regular postoperative 
follow-up visits in the urologists’ office. We kept track of these visits and according 
to our follow-up algorithm urine samples were collected and postoperative 
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information was recorded. The following table describes the clinical and 
radiological variables evaluated after the surgical management of all patients.  
 
Table 4. Information collected during follow-up visits. 
 
Radiological information was assessed by the treating urologist and was included in 
the main database after a careful evaluation of the images in our Centricity, One 
View electronic imaging system (GE Healthcare, Barrington, IL, USA). Axial and 
coronal reconstruction images from the CT scans were evaluated to determine the 
presence and dimensions of the stones. Patients without CT scan, had a KUB and a 
renal ultrasound to assess stone characteristics and determine the presence of 
hydronephrosis. 
The grade of hydronephrosis was determined by evaluating CT scan axial images at 
the level of the renal pelvis and calices or transversal renal ultrasound images, 
according to the hydronephrosis classification previously discussed (Table 2, 
Chapter 1). Incidental findings on imaging studies, such as presence of renal cysts, 
tumors, or anatomical anomalies were detailed.  
 48 
Serum creatinine is routinely measured in patients before the surgical procedure. 
The value was recorded and the eGFR calculated using the CKD-EPI formula 
(Levey, 2009). Presence and total leukocyte count per µL of urine and normalized 
values of AKI biomarkers (according to urinary creatinine) were recorded. 
Healthy subjects from hospital staff were invited to participate as the control group. 
A medical interview was completed to evaluate previous medical conditions and to 
exclude family and personal history of kidney stones. A bilateral renal ultrasound 
was performed by a Urologist, transverse and axial views were evaluated to rule out 
the presence of hydronephrosis and kidney stones (Hitachi-Aloka, ProSound SSD 
3500, CT, USA; 3.5 Mhz convex transducer). A negative urinalysis was the last 
inclusion criteria for controls. Subjects with any abnormality in the renal ultrasound 
or an abnormal urinalysis were contacted to have an appointment with a general 
practitioner, and were excluded from the analysis.  
The recruitment period lasted 10 months, from March 2015 to January 2016. All 
follow-up visits were completed by February 2016. All patients and controls were 
assessed in the Urology Clinic at St. Joseph Health Care, London, Ontario.  
2.3 Urine sample collection 
Mid-stream urine samples from all participants were collected in a 100 mL sterile 
plastic urine container. A 8 mL conical urinalysis tube was used to collect a portion 
of the sample and sent for urinary creatinine measurement and routine urinalysis to 
the main laboratory facilities.  
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We centrifuged 10-15 mL of urine for 5 minutes at 1000 rpm at room temperature. 
The urine supernatant was aliquoted in 1.5 ml Eppendorf tubes and stored at -80C at 
our facilities for further AKI markers analysis. All initial samples were labeled with 
a unique study number and a research number to cross match and de-identify the 
results. Sample handling followed published recommendations to avoid 
denaturalization of the markers and were stored within 2 hours of initial collection 
(Parikh, 2014).  
2.4 Urine sample analysis 
Urinary creatinine was measured by enzymatic colorimetric method using the 
Roche Modular P Chemistry analyzer, and results were reported as mmol/L 
(reference ranges: male, 3.5-25mmol/L; female, 2.6-20mmol/L).  A conversion 
factor of 88.42 was used to express the creatinine concentration in mg/dl from 
µmol/L. Urinalysis was initially performed using dipstick (Multistix SG, Siemens, 
Germany) which includes chemical examination for protein, blood, glucose, 
ketones, gravity, nitrite, leukocytes and blood. A microscopic analysis was done 
only if the dipstick revealed abnormal results, and the total number of red and white 
blood cells (cells/high power field) was recorded. The normal range for 
microhematuria and leukocyturia in the microscopic examination is < 5 cells/hpf 
(Lab Test Information Guideline, SJHC). 
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2.5 AKI biomarker levels 
AKI marker analysis was comprised in 3 different assays; one each for KIM-1, 
Monomeric and Total NGAL. After finishing the recruitment phase the samples 
were thawed at room temperature and were analyzed according to the 
manufactures specifications of each of the ELISA kits. All urine samples were 
diluted to adjust the effective pH for each antibody reaction and the detection limit 
of each ELISA experiment.  
2.5.1 KIM-1  
A commercially available ELISA kit (Human TIM-1/KIM/HAV, R&D Systems, 
Minneapolis, MN, USA) was used to determine urinary KIM-1 concentration in all urine 
samples. The kit came with a microtiter plate coated with a KIM-1 antibody which binds 
to the KIM-1 molecules in the sample, HRP streptavidin which binds to KIM-1 antibody, 
TMB substrate which detects HRP streptavidin, KIM-1 standards and buffers. Either 
standards or 1:4 dilution of each urine sample followed by biotinylated antibody which 
interacts with the KIM-1 antibody followed by Streptavidin/Horseradish peroxidase was 
added to each well of the microtiter plate. In between each addition plate was incubated 
for 30min at room temperature with mixing at 200rpm. After final 30min TMB substrate 
was added.  A blue color was generated in the solution and the intensity of blue color was 
correlated to the number of KIM-1 molecules in the urine sample. Plate was incubated 
exactly 20min at room temperature and the reaction was stopped by changing the pH of 
the reaction mixture with stop solution.  Absorbance readings of each well at 590nm and 
260nm were recorded using the EON BIOTEK plate reader supplied with Gen5 software.   
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Background absorbance of each sample was corrected by subtracting the 260nm reading 
from that of relevant 590nm one.  This whole process was conducted in duplicates.  
Standard curve for each plate was created using the absorbance readings of standards and 
KIM-1 concentration of each sample (40samples / plate) were calculated. 
2.5.2 Total NGAL  
The total NGAL ELISA kit (Bioporto Diagnostics, Hellerup, Denmark) was used to 
determine the concentration of total NGAL (the three different isoforms of NGAL: 
monomeric, homodimeric and MMP-9/NGAL) in urine samples (Pedersen, 2010). 
Analysis method was same as KIM-1 but with the plates were coated with antibodies 
which were specific for total NGAL and the incubation period after each addition was 1 
hour instead of 30mins. Urine samples used in this analysis were diluted in 1:500 
according to the manufacturer’s instructions. 
2.5.3 Monomeric NGAL 
Monomeric NGAL was measured using a commercially available Monomeric 
NGAL ELISA kit (Bioporto Diagnostics, Hellerup, Denmark) which contains 
Monomeric NGAL specific antibody coated microtiter plate.  Analysis procedure 
was exactly same as that of total NGAL 
Absorbance values that were lower or higher than the detection limit of each 
analysis were re-analyzed using either lower or higher sample dilutions. Each of the 
obtained values for all three biomarkers was normalized against creatinine levels of 
the relevant urine sample by simple division, using the following formula: 
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2.6 Statistical analysis 
Our main hypothesis stated that urinary biomarkers would be significantly different 
before and after the relief of the obstruction. We have formulated the following 
hypothesis for the statistical analysis, allowing an  α=0.05:  
HO: Median preoperative biomarker levels = Median postoperative biomarker levels 
HA: Median preoperative levels ≠ Median postoperative levels 
Demographic, clinical and biochemical characteristics were analyzed depending on the 
type of variable. Appendix 5 describes the coding of all the analyzed variables during the 
recruitment and follow-up of participants. Correlation between hydronephrosis grade and 
urine marker levels was evaluated with Spearman coefficient. Continuous variables were 
analyzed with Shapiro-Wilk test to determine the normality of the data distribution. 
Dichotomous variables were analyzed using Chi-square and Fisher’s exact test and 
continuous variables were compared with T-student or Mann-Whitney U test according to 
the type of distribution.  
The non-parametric Levene’s test was used to evaluate the variances between the the 
distribution of the biomarkers levels in the entire cohort. Normalized urine marker levels 
were assessed among the different groups using Mann-Whitney U test. Median 
     
    [AKI marker] ng/mL   =    [AKI marker ] ng/mg Creatinine 
[Urine Creatinine] mg/mL 
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preoperative and postoperative levels were compared with the Wilcoxon signed rank test. 
We evaluated the correlation between urinary biomarkers levels and presence of 
leukocyturia, stone disease, grade of hydronephrosis and eGFR. De-identified biomarker 
results, clinical and radiological data were stored in an electronic database and all 
information was analyzed with SPSS v.20 (Armonk, NY, IBM), P-values were derived 
from 2-tailed test, and a p<0.05 was considered statistically significant.  
2.7 Funding 
The study was partially funded by an unrestricted Internal Research Fund award granted 
to the investigator team by the Department of Surgery, Schulich School of Medicine & 
Dentistry.  
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3 Results 
We were able to complete the recruitment and follow-up of patients according to the 
previously calculated sample size. We decided to initially analyze the urinary 
biomarkers’ concentration of only the first and third urine sample, to avoid the possibility 
of highly abnormal values related to the presence of leukocytosis in patients with ureteric 
stent. These initial results would provide some light about the practicality of evaluating 
the second urine sample and save cost of this research project, because high values would 
require repeating ELISA analysis, which may increase the initial planned budget.  
A total of 66 patients and 12 controls were initially included in our study. Figure 7 is the 
flow diagram of the cohort, which shows that 9 patients were initially excluded from 
further follow-up due to incomplete baseline information or changes in their management 
strategy. A total of 44 patients completed the follow-up; 24 from the hydronephrosis 
group and 20 from the no hydronephrosis group. Some patients spontaneously passed the 
stone and some others decided to have their clinical follow-up in another city after the 
surgical intervention. Only one control subject had an abnormal urinalysis, and was 
excluded from the study. Postoperative assessment was conducted with a median of 68 
days (IQR 47). 
The main hypothesis involved the comparison of AKI markers in patients with 
hydronephrosis, and the number of patients recruited fulfilled the sample size calculation. 
The statistical analysis for the secondary hypotheses comprised the information from all 
patients included in the no hydronephrosis group and the 24 patients who completed the 
follow-up in the hydronephrosis group. 
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Figure 7: Flow chart of patients recruited and patients included in the final analysis. 
 
3.1 Expression of biomarkers in the hydronephrosis group 
A total of 24 patients recruited in the hydronephrosis group completed the follow-up. 
Stone disease was the most common cause of obstruction in our hydronephrosis cohort 
(22/24 patients), while one patient had congenital UPJO obstruction and one had an 
acquired ureteric stricture in the mid-ureter. In 63% of the cases the diagnosis was made 
78 Subjects
Total Recruited
66 patients 12 Controls
33 patients
Hydronephrosis
Group 1
24 patients
No Hydronephrosis 
Group 2
9 patients
Excluded
24 patients
Completed Study
20 patients
Completed Study
1 Control
Excluded
9 patients
Lost to follow up
4 patients
Lost to follow up
11 Controls
Completed Study
Excluded patients: 4 patients did not have follow-up at our center; 3 patients had not finished the follow up at the end of the recruitment 
phase and the surgical plan changed in 2 patients after initial enrollment. Excluded controls: one with abnormal urinalysis. All patients 
described as “Lost to follow up” were missed in the postoperative visits or had incomplete radiological studies.
Group 3
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after an episode of acute renal colic, and most of the patients showed moderate 
hydronephrosis (grade 2,3) at the time of enrollment. According to the serum creatinine 
values, only 4 patients had abnormal preoperative levels, and the median eGFR of the 
group was 85 ml/min/1.73m2.  
Twenty patients had a ureteroscopy performed, two patients passed the stone while 
waiting for the surgical treatment, one had a PCNL to deal with a stone located in the 
renal pelvis, and one patient had a robotic pyeloplasty. All procedures were performed 
without complications, and one patient with an impacted ureteric stone required 
placement of a nephrostomy tube to relieve the obstruction. After completing follow-up, 
all patients were stent free and 21 patients did not have hydronephrosis in the 
postoperative studies, and 7 showed residual stone fragments. Only three patients had 
hydronephrosis at the last study evaluation, two of them had had an impacted ureteric 
stone associated with grade 4 hydronephrosis and the patient with UPJO had mild 
hydronephrosis during the last follow-up visit.  
Demographic characteristics were similar between patients and controls. Table 5 shows 
the comparison in the demographic, clinical and radiological characteristics. The 
distribution of the absolute and normalized values of Total NGAL, Monomeric NGAL 
and KIM-1 were statistically significantly different between hydronephrotic patients and 
controls. Figure 8 shows the boxplot graphs of the normalized levels of the three urine 
biomarkers in the hydronephrosis and control groups.  
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Table 5. Comparison between preoperative characteristics of hydronephrosis group 
patients and controls. 
 
Hydronephrosis 
Group
Controls p value 
n= 24 11
Age Median (years), IQR 58.5, 15 50, 21 0.09
Gender Female/ Male 9/15 4/6 0.66 
BMI Median (kg/m2), IQR 30.7, 11.6 27.9, 9 0.14 
CCI Median (IQR) 1 (3) 1(1) 0.16
6/9
13
15
Imaging study CT scan/Renal ultrasound 16/8
Stone 22
UPJO/Stricture 2
Renal pelvis/UPJO 1/1
Ureter 22
Ureteroscopy 22
Pyeloplasty 1
Endopyelothomy 1
Side L/R 12/12
Largest diameter of stone Median (mm),  IQR 7 (4)
Hydronephrosis Grade 1 / 2 / 3 / 4 4 / 12 / 6/ 2
Preoperative S Cr Median (mmol/L) 85.5 (32)
Preop eGFR Mean (ml/min) 78.25 (29)
16
5
7 0 0.045
ABS KIM-1 Median ng/dl, (IQR) 0.782 (2.57) 0.376 (0.43) 0.017
NORM KIM-1 Median, (IQR) 1.19 (1.87) 0.36 (0.8) 0.020
ABS Total  NGAL Median ng/dl, (IQR) 15.84 (28.69) 8.72 (11.80) 0.030
NORM Total NGAL Median, (IQR) 21.84 (64.46) 6.32 (8.45) 0.009
ABS mNGAL Median ng/dl, (IQR) 12.96 (16.01) 8.33 (10.60) 0.017
NORM mNGAL Median, (IQR) 17.54 (25.85) 5.14 (8.44) 0.016
  ABS: absolute; BMI, body mass index; CCI, Charlson Comorbidity Index; mNGAL, Monomeric 
NGAL; NORM: normalized values expressed in ng/mg creatinine; S Cr: serum creatinine.     Chi-
square test for categorical variables and Student-T test or Mann Whitney-U test for continuous data. 
Table 5. Comparison between baseline characteristics of patients with hydronephrosis and 
control group
Patients with eGFR < 90 ml/min/1.73m2
Patients with eGFR < 60 ml/min/1.73m2
Diabetes/Hypertension
Previous history of stone disease
Diagnosis related to acute renal colic
Leukocyturia
Cause of obstruction
Planned procedure
Site of obstruction
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Figure 8. Boxplot graph showing the distribution of normalized values of 
biomarkers in patients with hydronephrosis and controls. 
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Except for three patients, all others in the hydronephrosis group showed a decreased 
urinary level of KIM-1 in the postoperative visit compared to the preoperative 
concentration. One of those three patients had pre-existing CKD and residual 
hydronephrosis, the other two only showed leukocyturia and residual stone disease. 
Figure 9 is a waterfall plot that shows the change in the postoperative levels of KIM-1 
after surgical management of the 24 patients in the hydronephrosis group.  
 
 
Figure 9. Waterfall plot showing the change in KIM-1 levels before and after 
treatment in all patients from the Hydronephrosis Group. 
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Based on previous research, we designed this study to evaluate if the normalized urinary 
levels of the KIM-1 and Monomeric NGAL were different after treatment and relief of 
the unilateral obstruction (alternative hypothesis -HA-), the null hypothesis (H0) stated 
that the median levels of the biomarkers were similar before and after treatment. 
Wilcoxon Signed Rank test showed no significant differences in the Total and 
Monomeric NGAL levels, while on the contrary KIM-1 was statistically significantly 
lower after treatment (Table 6, Figure 10). Regarding Total and Monomeric NGAL the 
H0 was accepted, although it has to be rejected for KIM-1, accepting the fact that KIM-1 
levels significantly changed after relieving the unilateral obstruction.  
 
 
Table 6. Comparison of preoperative and postoperative urinary biomarkers' 
concentration. 
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Figure 10. Boxplot graph showing the distribution of normalized values of 
biomarkers in patients with hydronephrosis before and after treatment 
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Considering that 3 patients had residual hydronephrosis after the treatment and 7 patients 
had residual stone fragments, we performed a post hoc analysis excluding these 
postoperative samples. Results were similar, showing only significant differences in 
KIM-1 levels, after comparing 24 vs 21 patients (residual hydronephrosis) and 24 vs 15 
(residual hydronephrosis and/or stones) (Table 7).  
 
Table 7. Post hoc analysis including patients without residual hydronephrosis and 
residual stone after treatment. 
 
After resolution of the hydronephrosis, KIM-1 concentration decreased to levels that 
were statistically similar to of the control group (0.76 vs 0.36 ng/ml creatinine, p=0.36).  
3.2 Factors associated with biomarkers expression 
The results of the following sections are based on the inclusion of the baseline 
characteristics of all recruited patients with complete information and the urinary 
biomarkers’ concentrations of the first collected urine samples (preoperative). Some 
statistical analyses also integrated the results obtained from the control group, in this 
case, a note is made.  
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3.2.1 Comparison of biomarker levels in patients with and 
without hydronephrosis 
Demographic, radiological and biochemical characteristics of the two groups of patients 
are shown in Table 8. Both groups were comparable in terms of age, gender, 
comorbidities, and previous history of stone disease. Besides the obvious difference in 
the hydronephrosis status, we also found significant differences in the number of patients 
diagnosed after an episode of renal colic, the size of the treated stone and the 
preoperative serum creatinine (p<0.05). Despite the disparities in the preoperative 
creatinine levels, the calculated eGFR was similar between both groups. The number of 
patients with CKD stage ≥ 3 was significantly higher in the hydronephrosis group and no 
differences were found in the presence of leukocyturia. 
The distribution of the preoperative levels of the biomarkers is also shown in Table 8. 
Interestingly, patients with hydronephrosis had significantly higher levels of absolute and 
normalized KIM-1 compared to those patients without hydronephrosis. (p=0.035, 
p=0.006). Monomeric and Total NGAL failed to show a significant difference between 
the group of patients with hydronephrosis and those without it.  After comparing the 
postoperative levels in the two groups, we did not find any significant difference in the 
median values of KIM-1 (p=0.81), Total NGAL (p=0.89) or Monomeric NGAL 
(p=0.37).  
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Table 8. Comparison between hydronephrosis and no hydronephrosis groups. 
 
p value*
n= 24 24
Age Median (years), IQR 58.5, 15 57, 19 0.74
Gender Female/ Male 9/15 12/12 0.56
BMI Median (kg/m2), IQR 30.7, 11.6 29.5, 6.55 0.65
CCI Median (IQR) 1 (3) 2 0.61
6 3 0.46
9 11 0.77
10 9 1
Side L/R 16/17 15/10 0.38
15 4 0.0001
Largest diameter (axial) Median (mm) 7 8.5 0.021
Hydronephrosis Grade 0 0 24 0.0001
Grade 1 4 0
Grade 2 7 0
Grade 3 11 0
Grade 4 2 0
Preoperative S Cr Median (mmol/L) 85 75 0.043
Preoperative eGFR 
ml/min/1.73m2
Mean (ml/min) 76.9 84.5 0.21
16 13 0.17
7 0 0.016
Leukocyturia in 7 6 1
NORM KIM-1 Median, IQR 1.19 (1.87) 0.64 (0.88) 0.006
NORM Total NGAL Median, IQR 21.84 (64.46) 25.26 (40.7) 0.88
NORM mNGAL Median, IQR 17.54 (25.85) 22.76 (25.14) 0.35
Additional findings Cyst 2 3
Renal mass 2 1
Table 8. Comparison between baseline characteristics of hydronephrosis and no 
hydronephrosis groups.
Acute episode
Patients with eGFR < 90 ml/min/1.73m2
Patients with eGFR < 60 ml/min/1.73m2
*categorical variables were compared using Chi-square test; continuous variables were compared 
with Student's T-test or Mann-Whitney U test.  mNGAL: Monomeric NGAL; NORM: normalized 
values expressed in ng/mg creatinine; S Cr: serum creatinine.
Previous history of stone disease
Diabetes
Hypertension
1
Patients with 
hydronephrosis
Patients without 
hydronephrosis
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3.2.2 Correlations between biomakers and grade of 
hydronephrosis 
For the evaluation of these possible correlations, we included the preoperative 
information of all patients and controls. We used Spearman’s test to correlate the urinary 
levels of the normalized biomarkers and the grade of hydronephrosis. KIM-1 was the 
only biomarker showing a significant correlation with the grade of hydronephrosis, and a 
moderate correlation (rs=0.39, p=0.002). Total and Monomeric NGAL did not correlate 
with the grade of hydronephrosis. 
 
3.2.3 Correlations between biomarkers and renal function 
Serum creatinine levels were available for all recruited patients. Biomarkers’ levels from 
preoperative urine samples were used to evaluate a possible correlation with the renal 
function measured by serum creatinine, estimated GFR, and by CKD stage according to 
the Kidney Disease Improving Global Outcomes classification (KDIGO). We did not 
find any significant correlation for any biomarker (Table 9). Our hypothesis that KIM-1 
and Monomeric NGAL would correlate with the overall renal function was not proven. 
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Table 9. Correlation between normalized biomarkers’ values and different ways to 
assess renal function. 
 
3.2.4 Other correlation analyses with biomarker levels 
We explored the association of preoperative continuous variables with the concentrations 
of the biomarkers. The preoperative information from all patients (48) was used. The 
normalized values of all three biomarkers positively correlated with the Charlson 
Comorbidity Index, but after adjusting for the age, these correlations were no longer 
significant (p>0.05). No correlations were found between the mean largest diameter of 
the stone and the level of any biomarker.  
After analyzing the preoperative urine samples, the grade of leukocyturia showed a 
moderate correlation with the normalized levels of Total and Monomeric NGAL 
(rs=0.43, p=0.007, rs=0.45, p=0.001) respectively, similar correlations were found 
evaluating the postoperative urine sample, and these remain significant after adjusting 
for age and CCI. Patients showing leukocyturia in the preoperative urine sample had 
significantly higher levels of Total and Monomeric NGAL (p=0.016, p=0.010) than 
those patients without leukocyturia, independently of the group they belonged to. None 
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of those patients had significant findings in the urinalyses suggesting a urinary tract 
infection, and all postoperative urine samples were from stent free patients. KIM-1 was 
not associated with the presence of leukocyturia. KIM-1 levels were similar between 
patients with and without preoperative leukocyturia (p=0.01). 
To evaluate any possible correlation between the three urinary biomarkers, we analyzed 
the preoperative urine samples of all patients and controls. We found significant 
correlations between all the markers, from weak to strong, being higher between Total 
NGAL and Monomeric NGAL as it would be expected (Table 10). Interestingly, the 
strength of the correlations was different among patients without hydronephrosis 
compared to the coefficients of patients with obstruction (Table 11). 
 
 
Table 10. Correlation coefficients between normalized biomarker levels in the first 
urine sample. 
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Table 11. Correlation coefficients between preoperative biomarkers in both groups. 
 
The initial sample size calculation was formulated in line with previously reported KIM-
1 values. The inclusion of Monomeric NGAL analysis in our study, made it the first 
clinical trial evaluating this marker which previous reports suggesting it was more 
specific for AKI. In view of our results, we decided not to analyze the second urine 
sample of the patients, because results from Total and Monomeric NGAL would be 
affected by leukocyturia, which is expected with the presence of a ureteric stent.   
3.3 Biomarker expression in the no hydronephrosis group 
Demographic characteristics between the no hydronephrosis group and controls showed 
no differences, except for the presence of comorbidities measured by the Charlson 
Comorbidity Index (CCI): patients had a median CCI of 2, while controls had a median 
of 1. After comparing the normalized values of the biomarkers we found that Total and 
Monomeric NGAL were significantly different both in the preoperative and 
postoperative urine samples. KIM-1 measurements did not significantly differ at any 
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point of the follow-up between controls and patients in the no hydronephrosis group 
(Table 12). 
We also compared the preoperative and postoperative levels and we found that values 
were not statistically significantly different despite the intervention for the stone disease. 
(KIM-1 p=0.30, Total NGAL p=0.33, Monomeric NGAL p=0.25). Figure 11 is a before-
after graph of the KIM-1 in this group which shows comparable results despite the 
treatment. 
 
Figure 11. Before-after graph of KIM-1 levels in no hydronephrosis group. 
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Table 12. Biomarkers’ concentration between the no hydronephrosis group and 
controls. 
 
3.4 KIM-1 as a diagnostic test for hydronephrosis 
Using ROC Curve analysis with the preoperative urine sample of all patients, we were 
able to calculate the best cut-off point for normalized KIM-1 to predict the presence of 
hydronephrosis either in the preoperative CT scan or renal ultrasound. The area under the 
curve (AUC) was 0.73 (95% CI 0.58-0.87, p=0.006), and a KIM-1 value of 0.735 ng/mg 
creatinine was the balance point to achieve the highest sensitivity (75%) and specificity 
(67%) (Figure 12). The Positive Predictive Value (PPV) is 59% and the Negative 
Predictive Value (NPV) 77%.  
None of the other analyzed biomarkers showed a significant AUC to detect 
hydronephrosis. If we use the preoperative and postoperative urine samples with their 
imaging studies as independent events, the AUC to detect hydronephrosis for KIM-1 was 
0.69 (95% CI 0.58 - 0.81, p=0.003). 
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Figure 12. ROC curve for hydronephrosis detection using KIM-1.  
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4 Discussion and Conclusions 
We were able to complete the recruitment and follow-up of patients according to the 
previously calculated sample size. After these initial results we decided to analyze only 
the first and third urine sample to avoid the possibility of highly skewed values related to 
the presence of a ureteric stent in the second sample. We will see that because KIM-1 
was not affected by the presence of leukocyturia, further analysis of KIM-1 
concentration in the second urine sample will be performed. The sample size calculation 
was based on the previously reported urinary levels of KIM-1, but we also had planned 
to explore the expression of Total and Monomeric NGAL. In order to correct for 
individual urinary protein production and hydration status, the normalized biomarkers 
levels were used to perform the statistical analysis, as all the recent literature 
recommends (Hsu, 2015). The urinary levels of the three biomarkers in patients with 
hydronephrosis were statistical significantly different compared to the control group. 
This information has been proven by several urological studies, demonstrating that 
biomarkers are able to discriminate between healthy subjects and patients with the 
specific renal disease, such as obstruction or infection (Cost, 2013; Xie, 2014; Yilmaz, 
2009).  
We believe our results provide a comprehensive overview of the expression of the 
studied biomarkers in these groups of urological patients. According to our design, the 
findings are statistically strong enough to prove differences and similarities in the 
expression of KIM-1 in the three studied groups. The information was prospectively 
collected, and the statistical tests should be considered adequate for non-normally 
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distributed data. Specific assumptions for each test were taken into consideration to 
properly analyze all the variables in the different hypotheses involving the three 
biomarkers. We should be cautious in the interpretation of the results regarding the 
expression of Monomeric NGAL however, because of the exploratory nature of the study 
in this regard. We acknowledge that the negative results about Total and Monomeric 
NGAL could result from a small sample size, but the correlation noted with the levels of 
leukocyturia may affect their usefulness in urological patients. This observation should 
be taken into account if further studies are planned to assess these particular biomarkers.  
4.1 Biomarkers expression in hydronephrosis group 
Patients with hydronephrosis had significantly higher levels of urinary KIM-1 at baseline 
compared to at the end of the follow-up period, after the obstruction was relieved. 
Likewise, this group of patients demonstrated an increased level of urinary KIM-1 
compared to both patients with stone disease without obstruction and healthy control 
subjects. These results may corroborate the fact that hydronephrosis due to obstruction 
causes kidney injury measured by the increased expression of the biomarker. It could be 
designated as subclinical, because serum creatinine was within the normal limits, but 
slightly higher in the obstructed patients, compared to the other studied groups. If 
treatment decisions were to be based on serum creatinine levels, treatment might be 
delayed especially in patients with unilateral obstruction and normal contralateral kidney 
function.  
From our perspective, the most important finding is the fact that KIM-1 elevation 
appears to be related to the presence of obstruction.  As a reflection of the presence of 
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AKI injury, KIM-1 could potentially be used as a hydronephrosis biomarker in several 
clinical situations. More large-scale studies are needed to validate the feasibility of its 
widespread use as an accurate marker of obstruction.  
Most of the longitudinal studies about biomarkers expression in patients with 
hydronephrosis have evaluated pediatric patients. Karakus studied 4 urinary biomarkers, 
including Total NGAL and KIM-1, in patients with obstructive antenatal hydronephrosis. 
He found that all biomarkers were higher compared to the control group, and NGAL and 
KIM-1 decreased to the levels showed by control group 6 months after the surgery. 
Interestingly, urinary KIM-1 concentration of the control group was very similar to what 
Wasilewska and collegues found in another set of pediatric patients with UPJO, and to 
our findings (0.60 vs 0.58 vs 0.36 ng/mg creatinine) (Karakus, 2015; Wasilewska, 2010). 
We found that KIM-1 decreased after relieving the obstruction, but not as low as the 
control group (0.75 vs 0.36 ng/ml), and this could be explained by the time lapse 
between surgery and the collection of the second postoperative urine sample. In our case 
it was only 2 months, compared to 6 in Karakus’ study. The other reason might be the 
fact that patients in both studied groups already had some sort of CKD (29 out of 48 
patients had an eGFR < 90 ml/min), which could be associated with higher baseline 
levels of KIM-1. A recently published case-control study about urinary biomarkers of 
and risk for ESRD (End-Stage Renal Disease), revealed that patients with ESRD had 
increased levels of urinary biomarkers, specifically, patients who developed ESRD had a 
mean baseline KIM-1 level of 914 pg/mg creatinine (0.914 ng/mg creatinine) compared 
to controls who showed a median concentration of 665 pg/mg creatinine (0.665 ng/mg 
creatinine) (Foster MC, 2016).  
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Another objective of this study was to also evaluate a group of patients with obstruction 
who had undergone diuretic renography. These are usually patients with congenital 
UPJO who required this investigation for diagnosis. We wanted to explore the expression 
of these markers before and after treatment and compare it to the actual “gold standard” 
and the radiological appearance of hydronephrosis. Unfortunately, the actual recruitment 
of UPJO patients was quite low; only 4 patients were initially recruited and one finished 
the study. This patient showed a decreased urinary concentration of KIM-1 in the 
postoperative urine sample, despite showing residual hydronephrosis in the imaging 
studies. No definitive conclusion can be made, but the recruitment of patients with UPJO 
will continue in order to explore the relationship between urinary marker expression and 
obstruction evaluation by renography. Although studies in the pediatric population 
suggested the potential usefulness of these biomarkers, results cannot be extrapolated to 
adult patients because most of the pediatric patients with UPJO obstruction have 
antenatal hydronephrosis which may affect the development of the renal parenchyma and 
the subsequent expression of biomarkers (Karakus, 2016; Madsen, 2013). 
Urbschat and collegues in a cross-sectional study evaluated the expression of serum and 
urinary NGAL and KIM-1 in patients with “acute obstructive nephropathy”. Their main 
results were different from our findings: KIM-1 was similar between controls and 
patients, and serum and urinary NGAL was statistically significantly different between 
both groups; they concluded that NGAL could be a potential marker of postrenal AKI. 
An important drawback of this study is the fact that all included patients with acute renal 
colic were considered to have postrenal AKI, despite the presence of hydronephrosis or 
the serum creatinine level. Additionally, patients with renal colic without hydronephrosis 
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were included in the studied group. The authors concluded that NGAL and a “negative 
urinary KIM-1” may facilitate the diagnosis of postrenal AKI (Urbschat, 2014). On the 
contrary, Xie et al, found a correlation between the preoperative and early postoperative 
urinary levels of KIM-1 in patients with obstructive nephropathy with the recovery of 
renal function 1 year after obstruction management. This conclusion raises the possibility 
of using KIM-1 not only as a diagnostic test, but also as an objective prognostic tool in 
patients with obstructive nephropathy (Xie, 2014). Sabbisetti also found the prognostic 
value of serum KIM-1 to predict the loss of GFR in diabetic patients with CKD 
(Sabbisetti, 2014).  
Whether KIM-1 has a protective role in cases of acute injury, or promotes a fibrotic 
process by its chronic expression, remains to be determined (Humphreys, 2013; Yang, 
2015). Further details about its expression in the acute and chronic setting must be 
addressed in future basic and clinical research. 
The urinary levels of Total and Monomeric NGAL were similar in patients with 
hydronephrosis before and after the relief of the obstruction, corroborating the absence of 
hydronephrosis with imaging studies in 21 of the 24 patients. All postoperative analyzed 
urine samples came from stent free patients. We determined if the presence of residual 
hydronephrosis affected the NGAL levels using a post hoc analysis. By excluding cases 
with residual hydronephrosis or stone fragments after the procedure, we did not find 
significant differences in Total and Monomeric NGAL concentrations.  
We believe that by including patients without urgent indications for active management, 
we automatically excluded patients with systemic inflammatory response symptoms 
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(SIRS) from our trial. This allowed a more objective measurement of the impact of 
hydronephrosis in the expression of Total and Monomeric NGAL by removing 
inflammation as a potential cause from NGAL release. 
Despite many research studies concluding that urinary and serum NGAL are reliable 
markers of AKI in other populations, Martensson and Bellomo discussed some reasons 
that may explain the differences in the diagnostic performance of NGAL for AKI in the 
published literature: 1) the use of creatinine as a “gold standard” to compare the global 
renal function may affect the sensitivity of the biomarker in “serum creatinine false-
negative AKI”, 2) chronic comorbidities that may affect the baseline expression of 
NGAL (i.e. CKD) 3) variations in the time lapse of biomarker measurement, and 4) the 
absence of specific essays to differentiate between the different NGAL isoforms 
(Martensson, 2014). In our study, we tried to account for one of those factors by 
measuring the Monomeric NGAL isoform.  
We are the first group to explore the urinary expression of Monomeric NGAL using a 
new ELISA kit claiming to have < 1% of cross reaction with Homodimeric NGAL. We 
hypothesized that by measuring the monomeric isoform, which is more specific for 
tubular epithelial cells, the diagnostic performance for kidney injury would increase 
(Bangert, 2012; Cai, 2010; Nickolas, 2012). Total NGAL and Monomeric NGAL 
showed similar expression in the studied groups, and no associations were related to the 
presence of hydronephrosis. Furthermore, the median values in the postoperative 
evaluation were higher than the baseline levels, but differences were not significantly 
different.  
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After analyzing our results, and comparing them with the previous literature, we believe 
that urinary KIM-1 has shown a promising future as an AKI marker in urological 
patients. If future studies corroborate our findings, and they find a correlation between 
the biomarker levels and the baseline renal function, we may have an opportunity to 
evaluate the prognostic significance of a urinary marker in urological patients.  
We have proven that despite the presence of normal median values of serum creatinine, 
patients with unilateral ureteral obstruction have increased levels of urinary KIM-1 
which has been recognized as an accurate marker of early kidney injury. Given that 
serum creatinine has failed to accurately stratify our patients with UTO because it cannot 
detect “subclinical injury” and a substantial decrease in the glomerular filtration is 
needed to affect the serum levels of creatinine, KIM-1 emerges as a potential biomarker 
in this set of patients. 
Further research should be conducted to elucidate the physiology behind the expression 
of KIM-1 during acute and chronic renal injury. In addition, further work is required to 
assess the effect of unilateral obstruction in the biomarkers levels in the affected unit 
compared to the bladder.  
4.2 Biomarkers expression in studied groups: 
hydronephrosis vs no hydronephrosis 
Our results suggest that urinary KIM-1 has the potential to become a useful marker for 
subclinical AKI associated with the presence of unilateral urinary obstruction. The 
design of the study allowed the evaluation of KIM-1 expression in a longitudinal (before 
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and after treatment) and cross-sectional fashion: KIM-1 was significantly higher in 
patients with hydronephrosis compared to patients with stone disease and no 
hydronephrosis, with similar demographic and medical characteristics. While we found 
significant differences in the serum creatinine levels, the median eGFR between the two 
groups was similar, and the number of patients with eGFR < 90 ml/min was comparable, 
although the median serum creatinine value of both groups was within the normal limits.   
Several important findings need to be underlined to better understand our results: 
1)KIM-1 levels were higher in patients with hydronephrosis, 2) the median postoperative 
level of KIM-1 in the hydronephrosis group after treatment was similar to what patients 
without hydronephrosis showed after surgery (0.75 ng/ml creatinine), 3) median KIM-1 
level of the control group was significantly different only in the hydronephrosis group, 
and 4) despite the significant differences in Total and Monomeric NGAL levels between 
the hydronephrosis and control groups, the expression of these two markers was similar 
among the two groups of patients before and after relieving obstruction.  
Our study is the first to analyze the impact of biomarkers’ expression before and after 
treatment in such detail. As briefly mentioned, there have been some studies that 
evaluated KIM-1 expression in hydronephrotic adult patients: Ursbchat et al did not find 
differences in the expression of urinary KIM-1, but they compared patients with acute 
renal colic without differentiating the presence or absence of hydronephrosis. Their 
results regarding NGAL expression could be affected also by the presence of SIRS 
commonly associated with renal colic. We mentioned that Xie and colleagues found that 
KIM-1 was a good predictor of AKI and a prognostic tool to determine the recoverability 
of renal function after an episode of obstructive nephropathy. These results should be 
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cautiously evaluated because the mean eGFR of the included patients was 11.5 
mL/min/1.73m2, and those with better function recovery had a mean eGFR 53.5 
mL/min/1.73m2 showing a large proportion of patients with late stages of CKD, and the 
results might not be reproduced in patients with normal eGRF (Xie, 2014; Xue, 2014).  
We also compared the levels of the three biomarkers in patients without hydronephrosis 
to the control group. Table 12 showed that both Total and Monomeric NGAL were 
different between preoperative and postoperative samples in the no hydronephrosis 
group in comparison with the controls. If these markers were good parameters of AKI in 
our population we would expect to be similar in the absence of hydronephrosis. Only 
KIM-1 was comparable in those groups, irrespectively of the presence of urolithiasis, 
suggesting that urinary KIM-1 is only affected by the presence of hydronephrosis.  
4.3 KIM-1 correlated with the grade of hydronephrosis 
In our study, KIM-1 was the only biomarker associated with the grade of 
hydronephrosis. After evaluating the performance of Total and Monomeric NGAL in 
both groups of patients, the correlation analysis confirms that these urinary biomarkers 
are not accurate enough to detect hydronephrosis in patients with co-existing conditions 
associated with urinary tract inflammation. In fact, the difference in the preoperative and 
postoperative levels was not statistically significant, although numerically both 
biomarkers were elevated. This previous finding was not expected, based on the 
published information as we hypothesized that at least Monomeric NGAL would have 
better correlation than Total NGAL with the occurrence of hydronephrosis. The grade of 
hydronephrosis positively correlated with the expression of KIM-1. Despite the fact that 
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the 24 patients with hydronephrosis were divided by 4 grades, which may have 
decreased the chances of finding an association, we found a moderate correlation 
between both variables. We envision a large scale multicentric study which may be able 
to corroborate our findings, especially about the the impact of baseline renal function in 
the expression of KIM-1. Such a study may evaluate the likelihood of using KIM-1 as a 
potential tool to stratify the management of patients with hydronephrosis according to 
the baseline renal function.  
Postoperative KIM-1 levels in patients with hydronephrosis were lower than before 
obstruction management, and almost all patients without hydronephrosis in the follow-up 
studies had decreased levels. While measuring the concentration of biomarkers in voided 
urine specimens may reflect the status of both renal units, and possibly “dilute” the 
biomarkers concentration of the affected unit, we aimed to assess an easy to perform and 
non-invasive test. The idea of evaluating the unilateral expression of the biomarkers 
would require an invasive procedure such as percutaneous nephrostomy insertion or 
retrograde catheter placement to collect urine from the affected unit. A ROC analysis 
showed that KIM-1 had a sensitivity of 75% and specificity of 67% to detect 
hydronephrosis. We believe this outcome deserves further evaluation in a large 
prospective cohort study to increase the number of patients with the different grades of 
hydronephrosis. The small number of patients in each of the hydronephrosis grade 
categories precluded a more specific analysis by each individual category.  
4.4 Biomakers and overall renal function 
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Several studies have shown a correlation between the AKI markers expression and renal 
function. Malyszko and collegues evaluated KIM-1 and NGAL in blood of patients after 
successful kidney transplantation, and the later had a strong correlation with serum 
creatinine levels (Malyszko, 2010). In our previous study, we found a higher level of 
urinary KIM-1 in patients with CKD compared to those with normal eGFR (Fahmy, 
2013). Based on this and other findings previously discussed, we expect a certain grade 
of correlation between renal function and the biomarkers’ baseline levels. None of the 
three evaluated biomarkers showed a significant correlation with the renal function 
measured by serum creatinine or the calculated eGFR. Furthermore, the CKD categories 
did not affect the baseline levels of any marker.  
One important fact that should be addressed, is that serum creatinine might not be the 
best reference standard, despite being the most commonly used test to measure global 
kidney function (Siew, 2011). The time between the acute episode of obstruction and the 
inclusion of the patients varied in this study. All patients were recruited in the Urology 
Clinic without needing an urgent intervention, which may affect the acute expression of 
the markers. This needs further evaluation, because the increment of creatinine levels 
depends on the individual renal reserve and the length of time between the renal insult 
and the evaluation.  
McIlroy prospectively evaluated the relationship between urinary NGAL and baseline 
renal function in patients undergoing cardiac surgery. They found a positive relationship 
between these two variables only in patients with an eGFR > 60 ml/min (McIlroy, 2009). 
This study included more than 400 patients and showed no differences in the 
perioperative NGAL levels despite the development of AKI in patients with CKD stage 4 
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and 5, which underlies the importance of baseline renal function on the biomarkers 
expression. Besides the fact that NGAL might be affected by the presence of 
leukocyturia, and these patients usually have a bladder catheter, they showed an 
association only in patients with normal baseline function. The small sample size of our 
study precluded the possibility of finding a positive relationship between the renal 
function and the eGFR.  
Although it was found that KIM-1 levels decreased after the treatment of the 
hydronephrosis, and that the perioperative values of KIM-1 in patients without 
hydronephrotic were similar to the control group, they were numerically higher. This 
finding might be explained by the fact that patients had some degree of CKD compared 
to the controls, assuming that subjects included in the control group had normal renal 
function. One limitation of this study is the fact that serum creatinine was not measured 
in the control group, and despite enrolling patients without significant comorbidities and 
assuming a normal renal function, the actual serum creatinine and eGFR were not 
available for analysis.  
4.5 Other factors related to biomarkers’ expression 
Initially, we found a moderate correlation analysis between age, Charlson Comorbidity 
Index, eGFR and the biomarkers’ expression. After adjusting for other clinical variables 
however, this correlation was not found to be significant. No other demographic or 
medical variables evaluated were correlated with the biomarkers’ levels. 
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Ours is not the first study showing an association between leukocyturia and the 
expression of any of the biomarkers. As we previously discussed, a case-control study 
found that urinary levels of NGAL were higher in patients with UTI than in controls; the 
same group in another study found a correlation between NGAL and the grade of 
leukocyturia (Urbschat, 2014). Decavele et al studied the urinary expression of NGAL 
and the presence of white cells in urine and concluded that high count of leukocytes 
contributes to the expression of urinary NGAL, and proposed a correction factor to 
increase the accuracy of the test (Decavele, 2011). The authors used a different assay to 
analyze the levels of NGAL precluding the use of their formula in our study, 
nevertheless our results showed a significant correlation between both Total and 
Monomeric NGAL and the presence of leukocyturia. 
We recognize that leukocyturia is a very common finding in urological conditions, and 
despite the use of a more specific isoform to detect subclinical AKI such as Monomeric 
NGAL, the nature and origin of the NGAL molecule may preclude its use in this set of 
patients. Leukocyturia may be caused by the presence of residual stone disease, urinary 
infection, or by the presence of indwelling catheters or ureteric stents.  
KIM-1 seems to be expressed in the voided urine specimen without any significant 
correlation with the presence of leukocyturia. In a previous study, assessing the impact of 
endourological management in the expression of KIM-1, we found that ureteroscopy did 
not significantly affect the urinary levels of KIM-1 (Nader, 2013). This is of particular 
importance because in this cohort study we analyzed postoperative samples at a median 
follow-up of two months after the surgical procedure. Both studies support the fact that 
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inflammatory conditions of the urinary tract, specifically stone disease or endourological 
manipulations, do not affect the levels of KIM-1.  
Our study answered some questions regarding the expression of these markers in 
urological patients. Most of the large scale studies evaluating AKI biomarkers in the 
emergency department excluded patients with urological conditions. We have found that 
KIM-1 appears to be unaffected by the presence of kidney stones, and we corroborated 
the fact that leukocyturia could potentially affect the urinary levels of Total and 
Monomeric NGAL. Researchers may consider these facts when designing future studies 
about the impact of different renal conditions on the expression of AKI biomarkers.  
4.6 Limitations of the study 
Despite the prospective design of this cohort study and the meticulous criteria for patient 
inclusion and exclusion, our study is not without limitations. Due to the fact than we did 
not want to interfere with the standard of treatment, some patients had to be excluded 
from the final analysis. After the enrollment in the study, some patients had their follow-
up in another city or did not return for clinical and urinary biomarker evaluation due to 
missing their appointments. Furthermore, due to the nature of this observational study, 
the follow-up was not completely standardized and in some cases the clinical evolution 
of the patient changed the usual postoperative evaluation and the subsequent exclusion of 
the patients from the final analysis. Despite this, 48 out of 66 patients were included in 
the final analysis which allowed us to perform the planned analysis. It is accepted that 
cohort studies have the potential to experience information bias, meaning that the 
exclusion of subjects lost to follow-up may affect the results. For these reasons, and 
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specially after this type of exploratory study, our results need to be replicated in a larger 
group.   
We assumed that the renal function of the healthy subjects was normal, and this may be a 
limitation while trying to correlate the expression of the biomarkers with the eGFR, 
because these subjects were not included in that analysis. In order to facilitate the 
recruitment of controls, we decided not to evaluate this parameter. Along with this 
limitation, we did not measure the serum creatinine at the follow-up visits in the included 
patients because it is usually not within the standard of care. However, it may have 
helped determine if the changes in the evaluated biomarkers had a correlation with the 
evolution of this parameter after the resolution of the obstructive process. 
Another limitation is the fact that not all preoperative imaging studies were performed 
the same day patients gave the urine sample for biomarker analysis. The evaluated 
preoperative imaging study might not have reflected the dynamic evolution of the urinary 
tract obstruction. As we previously mentioned, this was due to the observational design 
of the study. All postoperative urine samples however, were collected the same day the 
imaging study was performed, reassuring the relationship between the absence of 
hydronephrosis and the decreased levels of KIM-1.  
The fact of including patients with different causes of hydronephrosis in group 1 (stone 
disease, UPJO, ureteric stricture) could be interpreted as a limitation, because the 
outcomes from a renal function perspective could be different. Nevertheless, the design 
was made to evaluate the impact of hydronephrosis in the levels of the biomarkers, 
independently of the cause. For this reason we determine that the exposure variable 
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would be the obstruction detected by imaging studies, and the main objective the urinary 
levels of the three biomarkers before and after the surgical management.  
We acknowledge that hydronephrosis is not a synonym of obstruction, and there are 
some conditions, as those discussed in Chapter 1, that are not associated with urinary 
tract obstruction. Nevertheless, the standard clinical practice in urology assumes that in 
the presence of a stone the associated hydronephrosis reflects an obstructive process. It is 
not clinically useful or ethical to perform a renogram to determine if these patients are 
truly obstructed in order to define the most appropriate management. Equivocal cases, 
where hydronephrosis is not always a sign of obstruction, such as in patients with UPJO, 
require a renogram with diuretic for correct diagnosis (Ozayar, 2015). We planned to 
include these patients, however, the number of adult patients presenting UPJO was low, 
and only one patient completed the study. 
4.7 Future directions 
These results have identified an association with hydronephrosis and the urinary 
expression of KIM-1. While Total and Monomeric NGAL did not show a correlation 
with the presence of hydronephrosis, our results support a possible relationship with 
leukocyturia, hindering its use in this population.  
The recruitment of patients with UPJO will continue in order to evaluate the correlation 
of these biomarkers with the renogram results, a study that is considered the “gold 
standard” for the diagnosis of urinary tract obstruction. As we previously discussed, 
some studies have evaluated the expression of these biomarkers in the pediatric 
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population, but there are no published studies with adult patients. We believe our results 
should be further evaluated in a large multicentric scale study including clinical and 
biomarker assessment in the acute renal colic event. KIM-1 analysis will be performed 
for the second urinary sample, and it will help to determine if the presence of double J 
stent affects the urinary concentration. As we previously mentioned, the analysis of the 
second urine sample for Total and Monomeric NGAL will not be performed in order to 
save economical resources.  
Although, several questions regarding the actual function and significance of these 
molecules that are expressed in early renal injury remain unanswered, this study adds 
important information to the existing literature and raises the interest of finding a reliable 
marker of obstruction, even in cases with subclinical AKI. On the other hand, KIM-1 
should be evaluated in future studies as a potential point-of-care test to rule out the 
presence of obstruction, where normal values may predict the absence of AKI and may 
save further imaging in patients with urinary tract obstruction.  
Future research is needed to corroborate if KIM-1 would be a sensitive and specific 
urinary test to detect AKI in urological patients. The promising implications in clinical 
practice include the possibility of prioritizing non-urgent management in patients with 
urinary tract obstruction, by having an objective measurement to detect AKI, but also the 
fact that KIM-1 seems to be not affected by inflammatory conditions may allow the 
inclusion of this set of patients in further research about these biomarkers.  
 
  
 89 
Bibliography 
Bangert K, Baer A, Hjortrup PB, Perner A, Otto L, Bioporto U. The Monomer is the 
Major Form of NGAL in Urine and Plasma in Severe Sepsis. J Am Soc Nephrol. 
2013;24(2010):2235. 
Bangert K, Rosenkilde N, Jørgensen JP, Baer A, Otto L, Bioporto U. Immunochemical 
Determination of Monomer , Homodimer and Total Neutrophil Gelatinase-Associated 
Lipocalin. J Am Soc Nephrol. 2012;23:2012. 
Bellomo R, Ronco C, Kellum J a, Mehta RL, Palevsky P. Acute renal failure - definition, 
outcome measures, animal models, fluid therapy and information technology needs: the 
Second International Consensus Conference of the Acute Dialysis Quality Initiative 
(ADQI) Group. Crit Care. 2004;8(4):R204-R212.  
Bonventre J V. Kidney injury molecule-1: A translational Journey. TransAm Clin 
Climatol Assoc. 2014;125:293-299. 
Botto N, Azoulay R, Peuchmaur M, El Ghoneimi A. Renal parenchymal fibrosis and 
atrophy are not correlated with upper tract dilatation: Long-term study of partial 
unilateral ureteral obstruction in neonatal mice. J Pediatr Urol. 2011;7(3):310-316.  
Bouchard J, Acharya A, Cerda J, et al. A Prospective International Multicenter Study of 
AKI in the Intensive Care Unit. Clin J Am Soc Nephrol. 2015;10(8):1324-1331.  
Caddeo G, Williams ST, McIntyre CW, Selby NM. Acute kidney injury in urology 
patients: incidence, causes and outcomes. Nephrourol Mon. 2013;5(5):955-961.  
Cai L, Rubin J, Han W, Venge P, Xu S. The origin of multiple molecular forms in urine 
of HNL/NGAL. Clin J Am Soc Nephrol. 2010;5(12):2229-2235.  
Chertow GM. Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized 
Patients. J Am Soc Nephrol. 2005;16(11):3365-3370. 
Chevalier RL, Forbes MS, Thornhill B a. Ureteral obstruction as a model of renal 
interstitial fibrosis and obstructive nephropathy. Kidney Int. 2009;75(11):1145-1152.  
Cho KS, Hong SJ, Cho NH, Choi YD. Grade of Hydronephrosis and Tumor Diameter as 
Preoperative Prognostic Factors in Ureteral Transitional Cell Carcinoma. Urology. 
2007;70(4):662-666.  
Cochrane  a. L. Renal Structural and Functional Repair in a Mouse Model of Reversal of 
Ureteral Obstruction. J Am Soc Nephrol. 2005;16(12):3623-3630. 
doi:10.1681/ASN.2004090771. 
Cost NG, Noh PH, Devarajan P, et al. Urinary NGAL levels correlate with differential 
renal function in patients with ureteropelvic junction obstruction undergoing pyeloplasty. 
J Urol. 2013;190(4 Suppl):1462-1467.  
Decavele A-SC, Dhondt L, De Buyzere ML, Delanghe JR. Increased urinary neutrophil 
gelatinase associated lipocalin in urinary tract infections and leukocyturia. Clin Chem 
Lab Med. 2011;49(6):999-1003. doi:10.1515/CCLM.2011.156. 
 90 
Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin 
Pediatr. 2011;23(2):194-200.  
Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a 
dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat 
Biotechnol. 2010;28(5):455-462.  
Fahmy N, Sener A, Sabbisetti V, et al. Urinary expression of novel tissue markers of 
kidney injury after ureteroscopy, shockwave lithotripsy, and in normal healthy controls. J 
Endourol. 2013;27(12):1455-1462.  
Fernbach SK, Maizels M, Conway JJ. Ultrasound grading of hydronephrosis: 
Introduction to the system used by the society for fetal urology. Pediatr Radiol. 
1993;23(6):478-480.  
Gaygısız Ü, Aydoğdu M, Badoğlu M, Boyacı N, Güllü Z, Gürsel G. Can admission 
serum cystatin C level be an early marker subclinical acute kidney injury in critical care 
patients? Scand J Clin Lab Invest. 2016;76(2):143-150.  
Glassford NJ, Schneider AG, Xu S, et al. The nature and discriminatory value of urinary 
neutrophil gelatinase-associated lipocalin in critically ill patients at risk of acute kidney 
injury. Intensive Care Med. 2013;39:1714-1724. doi:10.1007/s00134-013-3040-7. 
Guerin F, Azoulay R, Berrebi D, et al. Partial Unilateral Ureteral Obstruction in Newborn 
Mice: Magnetic Resonance Imaging and Pathology Studies. J Urol. 2008;179(4):1553-
1563. 
Holzscheiter L, Beck C, Rutz S, et al. NGAL, L-FABP, and KIM-1 in comparison to 
established markers of renal dysfunction. Clin Chem Lab Med. 2014;52(4):537-546.  
Hou J, Fujino M, Cai S, Ding Q, Li X-K. Noninvasive Monitoring and Evaluation of the 
Renal Structure and Function in a Mouse Model of Unilateral Ureteral Occlusion Using 
Microcomputed Tomography. Int Surg. 2015;100(7-8):1237-1243.  
Hsu C -y., Ballard S, Batlle D, et al. Cross-Disciplinary Biomarkers Research: Lessons 
Learned by the CKD Biomarkers Consortium. Clin J Am Soc Nephrol. March 2015:1-9.  
Ichimura T, Bonventre J V., Bailly V, et al. Kidney injury molecule-1 (KIM-1), a 
putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is 
up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135-4142.  
Ingelfinger JR, Marsden P a. Estimated GFR and risk of death--is cystatin C useful? N 
Engl J Med. 2013;369(10):974-975.  
Irkilata L, Aydin HR, Demirel HC, Aydin M, Daggullu M. Is urinary kidney injury 
molecule-1 a noninvasive marker for renal injury in patients with ureteral stones? Arch 
Clin Exp Surg. 2015.  
Ito Y, Kikuchi E, Tanaka N, et al. Preoperative hydronephrosis grade independently 
predicts worse pathological outcomes in patients undergoing nephroureterectomy for 
upper tract urothelial carcinoma. J Urol. 2011;185(5):1621-1626.  
Karakuş S, Oktar T, Kucukgergin C, et al. Urinary IP-10, MCP-1, NGAL, Cystatin-C and 
KIM-1 Levels in Prenatally-Diagnosed Unilateral Hydronephrosis: the Search for an 
Ideal Biomarker. Urology. 2015;87:185-192.  
 91 
Keddis MT, Rule AD. Nephrolithiasis and loss of kidney function. Curr Opin Nephrol 
Hypertens. 2013;22(4):390-396. doi:10.1097/MNH.0b013e32836214b9. 
Kerr WS. Effects of complete ureteral obstruction in dogs on kidney function. Am J 
Physiol. 1956;184(3):521-526. 
Khan F, Ahmed K, Lee N, Challacombe B, Khan MS, Dasgupta P. Management of 
ureteropelvic junction obstruction in adults. Nat Publ Gr. 2014;11(11):629-638.  
Kjeldsen L, Johnsen  a H, Sengeløv H, Borregaard N. Isolation and primary structure of 
NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 
1993;268(14):10425-10432. 
Koyner JL, Vaidya VS, Bennett MR, et al. Urinary biomarkers in the clinical prognosis 
and early detection of acute kidney injury. Clin J Am Soc Nephrol. 2010;5(12):2154-
2165.  
Kristman V, Côté P. Loss to follow-up in cohort studies: How much is too much? Eur J 
Epidemiol. 2004;19(8):751-760. 
Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 
2005;365(9457):417-430.  
Loo MH, Felsen D, Weisman S, Marion DN, Vaughan ED. Pathophysiology of 
obstructive nephropathy. World J Urol. 1988;6:53-60. 
Madsen MG. Urinary biomarkers in hydronephrosis. Dan Med J. 2013;60:1-20. 
Malyszko J, Koc-Zorawska E, Malyszko JS, Mysliwiec M. Kidney injury molecule-1 
correlates with kidney function in renal allograft recipients. In: Transplantation 
Proceedings. 42. 2010:3957-3959.  
Mårtensson J, Bellomo R. The Rise and Fall of NGAL in Acute Kidney Injury. Blood 
Purif. 2014;37(4):304-310.  
Mårtensson J, Xu S, Bell M, Martling C-R, Venge P. Immunoassays distinguishing 
between HNL/NGAL released in urine from kidney epithelial cells and neutrophils. Clin 
Chim Acta. 2012;413(19-20):1661-1667.  
McIlroy DR, Wagener G, Lee HT. Neutrophil gelatinase-associated lipocalin and acute 
kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic 
performance. Clin J Am Soc Nephrol. 2010;5(2):211-219.  
McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Reference intervals for urinary renal 
injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 
2014;8(10):1189-1197.  
Perrotti A, Miltgen G, Chevet-Noel A, et al. Neutrophil Gelatinase-Associated Lipocalin 
as Early Predictor of Acute Kidney Injury After Cardiac Surgery in Adults With Chronic 
Kidney Failure. Ann Thorac Surg. 2015;99(3):1-6.  
Miller NL, Lingeman JE. Management of kidney stones. BMJ. 2007;334(7591):468-472.  
Nakada SY, Hsu THS. Campbell-Walsh Urology. Vol Tenth Edit. Elsevier; 2012.  
Nickolas TL, Forster CS, Sise ME, et al. NGAL (Lcn2) monomer is associated with 
 92 
tubulointerstitial damage in chronic kidney disease. Kidney Int. 2012;82(6):718-722.  
Nickolas TL, O’Rourke MJ, Yang J, et al. Sensitivity and specificity of a single 
emergency department measurement of urinary neutrophil gelatinase-associated lipocalin 
for diagnosing acute kidney injury. Ann Intern Med. 2008;148(11):810-819.  
Ozayar A, Friedlander JI, Shakir N a., Gahan JC, Cadeddu J a., Morgan MSC. Equivocal 
Ureteropelvic Junction Obstruction on Diuretic Renogram—Should Minimally Invasive 
Pyeloplasty be Offered to Symptomatic Patients? J Urol. 2015;193(4):1278-1282.  
Parikh CR, Butrymowicz I, Yu A, et al. Urine stability studies for novel biomarkers of 
acute kidney injury. Am J Kidney Dis. 2014;63(4):567-572. 
Pedersen KR, Ravn HB, Hjortdal VE, Nørregaard R, Povlsen J V. Neutrophil gelatinase-
associated lipocalin (NGAL): validation of commercially available ELISA. Scand J Clin 
Lab Invest. 2010;70(5):374-382.  
Preminger GM, Tiselius HG, Assimos DG, et al. 2007 Guideline for the Management of 
Ureteral Calculi. J Urol. 2007;178(6):2418-2434.  
Shalabi A, Abassi Z, Awad H, et al. Urinary NGAL and KIM-1: potential association 
with histopathologic features in patients with renal cell carcinoma. World J Urol. 
2013;31(6):1541-1545.  
Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and 
cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049-2060.  
Siew ED, Ware LB, Ikizler T a. Biological Markers of Acute Kidney Injury. J Am Soc 
Nephrol. 2011;22(5):810-820.  
Singh I, Strandhoy JW. Pathophysiology of Urinary Tract Obstruction. Vol Tenth Edit. 
Elsevier Inc.; 2012. doi:10.1016/B978-1-4160-6911-9.00040-2. 
Sivalingam S, Stormont I, Nakada SY. Contemporary practice patterns in the 
management of acute obstructing ureteral stones. J Endourol. 2015; Ahead of Print.  
Sprenkle PC, Wren J, Maschino AC, et al. Urine Neutrophil Gelatinase-Associated 
Lipocalin as a Marker of Acute Kidney Injury After Kidney Surgery. J Urol. 
2013;190(1):159-164.  
Sugandhi N, Srinivas M, Agarwala S, et al. Effect of stem cells on renal recovery in rat 
model of partial unilateral upper ureteric obstruction. Pediatr Surg Int. 2014;30(2):233-
238.  
Türk C, Knoll T, Petrik A, et al. Pocket Guidelines on urolithiasis. Eur Urol. 
2014;40(4):362-371.  
Urbschat A, Gauer S, Paulus P, et al. Serum and urinary NGAL but not KIM-1 raises in 
human postrenal AKI. Eur J Clin Invest. 2014;44(7):652-659. 
Urbschat A, Obermüller N, Paulus P, et al. Upper and lower urinary tract infections can 
be detected early but not be discriminated by urinary NGAL in adults. Int Urol Nephrol. 
September 2014.  
Vaidya VS, Waikar SS, Ferguson M a, et al. Urinary Biomarkers for Sensitive and 
Specific Detection of Acute Kindey Injury in Humans. Clin Transl Sci. 2008;1(3):200-
 93 
208. 
Van De Vrie M, Deegens JK, Van Der Vlag J, Hilbrands LB. Effect of long-term storage 
of urine samples on measurement of kidney injury molecule 1 (KIM-1) and neutrophil 
gelatinase-associated lipocalin (NGAL). Am J Kidney Dis. 2014;63(4):573-576.  
van den Akker EK, Hesselink DA, Manintveld OC, IJzermans JNM, de Bruijn RWF, Dor 
FJMF. Neutrophil Gelatinase-Associated Lipocalin, but Not Kidney Injury Marker 1, 
Correlates with Duration of Delayed Graft Function. Eur Surg Res. 2015;55(4):319-327.  
Vinken P, Starckx S, Barale-Thomas E, et al. Tissue Kim-1 and urinary clusterin as early 
indicators of cisplatin-induced acute kidney injury in rats. Toxicol Pathol. 
2012;40(7):1049-1062.  
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation 
from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 
2014;14(1):135. 
Wang B, Chen G, Zhang J, Xue J, Cao Y, Wu Y. Increased Neutrophil Gelatinase-
Associated Lipocalin is Associated with Mortality and Multiple Organ Dysfunction 
Syndrome in Severe Sepsis and Septic Shock. Shock. 2015;44(3):234-238.  
Wen JG, Chen Y, Djurhuus JC. Experimental partial unilateral ureter obstruction. I. 
Pressure flow relationship in a rat model with mild and severe acute ureter obstruction. J 
Urol. 1998;160(4):1567-1571. 
Xie Y, Xue W, Shao X, et al. Analysis of a urinary biomarker panel for obstructive 
nephropathy and clinical outcomes. PLoS One. 2014;9(11):e112865.  
Xu SY, Pauksen K, Venge P. Serum measurements of human neutrophil lipocalin (HNL) 
discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest. 
1995;55(2):125-131.  
Xue W, Xie Y, Wang Q, Xu W, Mou S, Ni Z. Diagnostic performance of urinary kidney 
injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidney injury 
in an obstructive nephropathy patient. Nephrology (Carlton). 2014;19(4):186-194.  
Yang L, Brooks CR, Xiao S, et al. KIM-1-mediated phagocytosis reduces acute injury to 
the kidney. J Clin Invest. 2015;125(4):1620-1636. 
Yilmaz A, Sevketoglu E, Gedikbasi A, et al. Early prediction of urinary tract infection 
with urinary neutrophil gelatinase associated lipocalin. Pediatr Nephrol. 
2009;24(12):2387-2392. 79. Zappitelli M, Washburn KK, Arikan A a, et al. Urine 
neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in 
critically ill children: a prospective cohort study. Crit Care. 2007;11(4):R84.  
 
 
 
 94 
Appendix 1 - STROBE Statement 
 Item 
No Recommendation 
Section (Page) 
 Title and abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the abstract 
ü 
i 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what 
was found 
ü 
ii 
Introduction  
Background/rationale 2 Explain the scientific background and 
rationale for the investigation being reported 
ü 
Chapter 1 
Objectives 3 State specific objectives, including any 
prespecified hypotheses 
ü 
37-39 
Methods  
Study design 4 Present key elements of study design early in 
the paper 
ü 
40-43 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
ü 
45-48 
Participants 6 (a) Give the eligibility criteria, and the sources 
and methods of selection of participants. 
Describe methods of follow-up 
ü 
(b) For matched studies, give matching criteria 
and number of exposed and unexposed 
ü 
99 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 
modifiers.  
ü 
Chapter 2 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one 
group 
ü 
46-47, 101-102 
Bias 9 Describe any efforts to address potential 
sources of bias 
ü 
45-48 
Study size 10 Explain how the study size was arrived at ü 
44 
Quantitative 
variables 
11 Explain how quantitative variables were 
handled in the analyses. If applicable, describe 
which groupings were chosen and why 
ü 
52-53 
Statistical methods 12 (a) Describe all statistical methods, including 
those used to control for confounding 
ü 
52-53 
(b) Describe any methods used to examine 
subgroups and interactions 
ü 
 
(c) Explain how missing data were addressed ü 54 
(d) Explain how loss to follow-up was 
addressed 
 
(e) Describe any sensitivity analyses Not performed 
 95 
 
Results 
 
Participants 13* (a) Report numbers of individuals at each 
stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed 
eligible, included in the study, completing 
follow-up, and analysed 
ü 
54-55 
(b) Give reasons for non-participation  ü 
(c) Consider use of a flow diagram ü 
55 
Descriptive data 14* (a) Give characteristics of study participants 
(eg demographic, clinical, social) and 
information on exposures and potential 
confounders 
ü 
57 
(b) Indicate number of participants with 
missing data for each variable of interest 
ü 
 
(c) Summarise follow-up time (eg, average 
and total amount) 
ü 
54 
Outcome data 15* Report numbers of outcome events or 
summary measures over time 
ü 
59 
 
Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval).  
 
 
(b) Report category boundaries when 
continuous variables were categorized 
ü 
 
(c) If relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
 
 
Other analyses 17 Report other analyses done—eg analyses of 
subgroups and interactions, and sensitivity 
analyses 
ü 
62 
 
Discussion  
Key results 18 Summarise key results with reference to study 
objectives 
ü 
72 
 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
ü 
85-86 
Interpretation 20 Give a cautious overall interpretation of results 
considering objectives, limitations, 
multiplicity of analyses, results from similar 
studies, and other relevant evidence 
ü 
84-85 
Generalisability 21 Discuss the generalisability (external validity) 
of the study results 
ü 
78-80 
Other information  
Funding 22 Give the source of funding and the role of the 
funders for the present study 
ü 
53  
 96 
Appendix 2 – Western University Health Science Research 
Ethics Board Approval Notice 
 
 97 
Appendix 3 – Consent and Letter of Information 
 
 
 
 
 
 
Biomarkers of Kidney Injury in a Urological Population 
Version dated 9 December2014 
Page 1 of 3  Patient Initials:_______________________   
    
 
 
Biomarkers of Kidney Injury in a Urological Population 
 
Letter of Information 
 
Principal Investigator:   Dr. Hassan Razvi 
Co‐Investigators:    Dr. Stephen Pautler & Dr. John Denstedt 
         
INTRODUCTION 
You have been asked to voluntarily participate in this research study because you have been scheduled for 
treatment/surgery for your kidney stone(s).  
 
PURPOSE 
The purpose of this study  is to analyse your urine for the presence of some proteins that your kidney may 
release due to stone disease and/or an obstructed kidney. These protein biomarkers may be helpful  in the 
future diagnosis and management of patients with these urological conditions. 
 
STUDY SELECTION 
It is expected that 150 patients, both men and women, will be enrolled, at St. Joseph’s Hospital, St. Joseph’s 
Health Care London.  
 
PROCEDURES 
If you agree to participate,  information about you (age and gender) and about your medical and urological 
history as well as information about your current urinary condition and treatment will be collected.  You will 
be  asked  to  provide  a  voided  urine  sample  before  your  surgery  and  again  at  each  of  your  follow‐up 
appointments at 3 to 6 weeks and again at 3 to 6 months, here at St. Joseph’s Hospital. 
 
A  portion  of  your  each  of  your  urine  samples  will  be  sent  to  the  hospital  laboratory  for  routine 
microscopy/chemistry and to test the level of creatinine (how well your kidneys filter waste). The remainder 
of each  sample will be  shipped  to  the Laboratory at Harvard University  for biomarker analysis.   The data 
from all participants will be compiled and the analysis will be done here at St. Joseph’s Hospital. 
 
RISKS 
The specific risks associated with your surgical procedure will be explained to you by your urologist. There 
are no known additional risks associated with your participation in this study.     
 
BENEFITS 
You will not receive any benefit from participating in this study. However, your participation in this research 
study may help future patients. 
 
PARTICIPATION 
Participation  in  this  study  is  voluntary.   You may  refuse  to participate,  refuse  to answer any question or 
withdraw  from  the  study at any  time with no effect on your  future care.   To protect  the  integrity of  the 
study, you will not be able to withdraw your data from the study after your urine samples have been  
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collected and sent for analysis.  You may also be withdrawn without your permission, if, in the opinion of the 
investigators, further participation would not be in your best interest.   
 
You do not waive any legal right by signing the consent form.  Every precaution will be taken to prevent any 
injury to you during the study.   However,  if an  injury does occur, you will obtain medical care  in the same 
way that you normally would obtain your medical care.   
 
ALTERNATIVES 
As  an  alternative  to  participation  in  this  study,  you may  choose  not  to  participate  and  no  urine will  be 
collected for the study.   
 
COMPENSATION 
You will not be paid for your time for taking part in this study.  
 
CONFIDENTIALITY 
All  information obtained during the course of this study  is strictly confidential.   You have a right to privacy 
and as permitted by applicable  law, all reasonable measures will be taken to protect the confidentiality of 
your records.  Your urine samples will be sent to the laboratory at Harvard University and will be identified 
only with a unique study number. Information resulting from this study and from your medical record may 
be used for research purposes and may be published.  However, you will not be identified personally in such 
publications.   All  research  records will be stored  in secure  research offices.   While we will do our best  to 
protect your information there is no guarantee that we will be able to do so.  
 
Information gathered  from  the  study will be made available  to  the  investigators.   Representatives of The 
University  of Western Ontario Health  Sciences  Research  Ethics  Board may  require  access  to  your  study‐
related records or may contact you to monitor the conduct of the research.   Representatives from Lawson 
Health Research Institute may require access your study record for quality assurance purposes. 
 
QUESTIONS / FURTHER INFORMATION 
Please keep this Letter of Information and if you have any questions about this study, please do not hesitate 
to contact your urologist or  the study coordinator.    If you no  longer wish  to participate  in  the study, you 
must let your urologist or the study coordinator know. 
Investigators/Urologists 
Dr. Razvi  519‐646‐6259    
Dr. Pautler  519‐646‐6384 
Dr. Denstedt  519‐646‐6036   
  The study Coordinator can be reached at   519‐646‐6310   
 
A copy of your signed consent form will be made available to you. 
 
If you have any questions about your rights as a research participant or the conduct of the study you may 
contact Dr. David Hill, Scientific Director, Lawson Health Research Institute at 519‐646‐4716.  
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CONSENT FORM 
 
 
 
I, __________________________________________________________________ have read 
the Letter of Information, have had the nature of the study explained to me and I agree to 
participate.  All questions have been answered to my satisfaction. 
 
 
 
__________________      _____________________________   
Date            Signature of Participant 
 
 
 
 
 
            ______________________________ 
Name of person responsible for  
obtaining this consent 
 
 
 
 
 
__________________      _____________________________   
Date            Signature of person responsible for  
obtaining this consent 
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Appendix 4 – Inclusion and Exclusion Criteria Checklists 
 
A) Patients  
 
 
 
Biomarkers of Kidney Injury in a Urological Population 
 
 
 
Patient Name:__________________________________________ JNumber:_____________________ 
 
Patients….  
 can only be enrolled once in this study; 
 must be planning on returning here for both follow-up appointments. 
 
INCLUSION & EXCLUSION CRITERIA 
 
 
_= Yes, INCLUSION CRITERIA 
Patients with ureteropelvic junction obstruction (UPJO) or 
ureteral stricture causing unilateral hydronephrosis: 
 Patients at least 18 years old; 
 Patients willing to provide informed consent; 
 Patients with diagnosis of UPJO or ureteral stricture  
 associated with unilateral hydronephrosis; 
 Patients with UPJO may have a renal stone, but it should 
not be the cause of the obstruction; 
 Patients with a diuretic renogram performed before the 
surgical intervention/procedure.  
 
_= No, EXCLUSION CRITERIA 
Patients with ureteropelvic junction obstruction (UPJO) or 
ureteral stricture causing unilateral hydronephrosis: 
 Active urinary tract infection; 
 Patients with an indwelling ureteric stent; 
 Use of indwelling bladder catheter; 
 Recent history of sepsis or septic shock (< 3 months); 
 If it is in the treating urologist’s opinion that participation 
in this study is not in the patient’s best interest.  
 
 
 
_= Yes, INCLUSION CRITERIA 
Patients with unilateral hydronephrosis due to stone disease 
without need for urgent management: 
 Patients at least 18 years old; 
 Patients with unilateral stone disease located in ureter or 
at ureteropelvic junction:  
 Patients with a CT KUB or KUB and renal ultrasound 
performed before the surgical intervention/procedure; 
 Presence of hydronephrosis on the affected side;  
 Patients with a serum creatinine measured no more than 
6 months before the surgical intervention/procedure; 
 Patients scheduled for PCNL or ureteroscopy to relieve 
the obstruction. 
_= No, EXCLUSION CRITERIA 
Patients with unilateral hydronephrosis due to stone disease 
without need for urgent management: 
 Contralateral hydronephrosis from any cause; 
 Active urinary tract infection; 
 Use of indwelling bladder catheter; 
 Recent history of sepsis or septic shock (< 3 months); 
 If it is in the treating urologist’s opinion that participation 
in this study is not in the patient’s best interest.  
 
_= Yes, INCLUSION CRITERIA 
Patients with stone disease without hydronephrosis: 
 Patients at least 18 years old; 
 Patients willing to provide informed consent; 
 Patients scheduled for PCNL or ureteroscopy to treat 
kidney stone(s); 
 Patients with CT KUB scan or a KUB and a renal 
ultrasound;  
 CT-KUB or renal ultrasound negative for 
hydronephrosis; 
 Patients with at least one determination of serum 
creatinine in the last 6 months. 
 
_= No, EXCLUSION CRITERIA 
Patients with stone disease without hydronephrosis: 
 Presence of a ureteric stent; 
 Active urinary tract infection; 
 Patients with hydronephrosis defined by dilation of 
renal pelvis or calyces seen on CT scan or renal 
ultrasound at least 3 months before the surgical 
procedure; 
 Use of indwelling bladder catheter; 
 Recent history of sepsis or septic shock (< 3 months); 
 If it is in the treating urologist’s opinion that 
participation in this study is not in the patient’s best 
interest.  
 
 
 
Comments: 
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B) Controls 
 
 
 
Biomarkers of Kidney Injury in a Urological Population 
 
 
 
 
Name:______________________________________________________________________________ 
 
 Subjects can only be enrolled once in this study. 
 
INCLUSION CRITERIA 
_= Yes 
 Healthy subjects (Control group): 
 At least 18 years of age; 
 Willing to provide informed consent;  
 Able to provide a voided urine simple; 
 Willing to have a renal ultrasound. 
 
 
EXCLUSION CRITERIA 
 
_= No 
 Healthy subjects (Control group): 
 Previous personal or family history of stone disease by patient history;  
 Abnormal renal ultrasound; 
 Abnormal dip-stick urinalysis: 
Blood, leukocytes, nitrites, proteins or glucose is positive.   
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Appendix 5 – Coding of the analyzed variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 5: Coding of analyzed variables
Demographics Type of Variable Values Units
Age Continuous 0-99 years
BMI Continuous 15-50 kg/m2
Gender Categorical, dichotomous Male, Female
CCI Categorical, ordinal 0->8
Diabetes Categorical, dichotomous Yes, No
Hypertension Categorical, dichotomous Yes, No
Previous stone disease Categorical, dichotomous Yes, No
Clinical
Episode related to renal colic Categorical, dichotomous Yes, No
Length of time from colic to enrollment Continuous 1-99 weeks
Planned procedure Categorical, nominal URS, PCNL, Pyeloplasty
Recent visit to ER Categorical, dichotomous Yes, No
Imaging study (CT scan/Renal US) Categorical, nominal CT Scan, Renal US
Presence and grade of hydronephrosis Categorical, dichotomous Yes, No
Presence of stone/ureteric stricture Categorical, dichotomous Yes, No
Grade of hydronephrosis (Modified 
Fernbach & Ito classification)
Categorical, ordinal 0-4
Single or multiple stone disease Categorical, dichotomous Single, Multiple
Location of the stone (kidney, UPJ, 
ureter)
Categorical, nominal Kidney, UPJ, Ureter
Largest diameter of stone Continuous 0-50 mm
Additional incidental findings in imaging Qualitative
Preoperative serum creatinine Continuous 50-500 mg/mL
eGFR according CKD-EPI formula Continuous 0-120 ml/min
Presence of leukocyturia in urinalysis Categorical, dichotomous Yes, No
Number of leukocytes in urine Continuous 0->500 cells/uL
Urinary creatinine Continuous 0-50 mg/mL
Absolute urinary levels of KIM-1, 
monomeric & homodimeric NGAL
Continuous 0-2000 ng/mL
Normalized urinary levels of KIM-1, 
monomeric & homodimeric NGAL Continuous 10-1000 ng/mg creatinine
Laboratory findings
Radiological
Past medical hisotry
Baseline variables
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Clinical
Presence of ureteric stent Categorical, dichotomous Yes, No
Radiological
Imaging study for follow up Categorical, nominal CT Scan, Renal US, KUB
Presence of residual stones Categorical, dichotomous Yes, No
Number of residual stones Categorical, dichotomous Single, mutiple
Presence and grade of hydronephrosis Categorical, dichotomous Yes, No
Grade of hydronephrosis (Modified 
Fernbach & Ito classification) Categorical, ordinal 0-4
Biochemical
Presence of leukocyturia in urinalysis Categorical, dichotomous Yes, No
Number of leukocytes in urine Continuous 0->500 cells/uL
Urinary creatinine Continuous 0-50 mg/mL
Absolute urinary levels of KIM-1, 
monomeric & homodimeric NGAL
Continuous 0-2000 ng/mL
Normalized urinary levels of KIM-1, 
monomeric & homodimeric NGAL
Continuous 0-100 ng/mg creatinine
Presence of incidental findings on 
imaging studies Qualitative
Units abbreviations: mg, miligram; mL, mililiter; ng, nanogram.
* CCI: Charlson Comorbidity Index; ER: Emergency Room; HTN: hypertension; KUB: kidney-ureter-bladder x-rays; 
UA: urinalysis; UPJ: ureteropelvic junction; US: ultrasound.
Follow-up
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